

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : C07D 215/22, 215/50, 215/42 C07D 215/46, 401/06, 413/06 A61K 31/47</p>	<p>A2</p>	<p>(11) International Publication Number: WO 93/11115 (43) International Publication Date: 10 June 1993 (10.06.93)</p>
<p>(21) International Application Number: PCT/GB92/02183 (22) International Filing Date: 25 November 1992 (25.11.92) (30) Priority data: 9125515.8 29 November 1991 (29.11.91) GB (71) Applicant (<i>for all designated States except US</i>): MERCK SHARP & DOHME LIMITED [GB/GB]; Hertford Road, Hoddesdon, Hertfordshire EN11 9BU (GB). (72) Inventors; and (75) Inventors/Applicants (<i>for US only</i>): CARLING, William, Robert [GB/GB]; 15 The Colts, Thorley Park, Bishops Stortford, Hertfordshire CM23 4DL (GB). LEESON, Paul, David [GB/GB]; 127 Mawson Road, Cambridge, Cambridge CB1 2DZ (GB). MOORE, Kevin, William [GB/GB]; 22 White Hart Close, Buntingford, Hertfordshire SG9 9DG (GB). ROWLEY, Michael [GB/GB]; 81 Hull Grove, Harlow, Essex CM19 5RR (GB).</p>		<p>(74) Agent: THOMPSON, John; Merck & Co., Inc., European Patent Department, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). (81) Designated States: CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>Without international search report and to be republished upon receipt of that report.</i></p>
<p>(54) Title: QUINOLONE DERIVATIVES (57) Abstract A class of 2-(1H)-quinolone derivatives, substituted at the 3-position by an optionally substituted aryl substituent, are selective non-competitive antagonists of NMDA receptors and/or are antagonists of AMPA receptors, and are therefore of utility in the treatment of conditions, such as neurodegenerative disorders, convulsions or schizophrenia, which require the administration of an NMDA and/or AMPA receptor antagonist.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SU	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TC	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

- 1 -

QUINOLONE DERIVATIVES

5 This invention relates to a class of 2(1H)-
quinolone derivatives which are substituted in the 3-
position by an optionally substituted aryl substituent.
These compounds are selective non-competitive antagonists
of N-methyl-D-aspartate (NMDA) receptors. More
particularly, the class of compounds provided by the
10 present invention are ligands for the strychnine-
insensitive glycine modulatory site of the NMDA receptor
and are therefore useful in the treatment and/or
prevention of neurodegenerative disorders arising as a
consequence of such pathological conditions as stroke,
15 hypoglycaemia, cerebral palsy, transient cerebral
ischaemic attack, cerebral ischaemia during cardiac
pulmonary surgery or cardiac arrest, perinatal asphyxia,
epilepsy, Huntington's chorea, Alzheimer's disease,
Amyotrophic Lateral Sclerosis, Parkinson's disease,
20 Olivo-ponto-cerebellar atrophy, anoxia such as from
drowning, spinal cord and head injury, and poisoning by
exogenous and endogenous NMDA receptor agonists and
neurotoxins, including environmental neurotoxins.

By virtue of their NMDA receptor antagonist
25 properties, the compounds according to the present
invention are also useful as anticonvulsant and
antiemetic agents, as well as being of value in the
prevention or reduction of dependence on dependence-
inducing agents such as narcotics.

30 NMDA receptor antagonists have recently been
shown to possess analgesic (see, for example, Dickenson
and Aydar, Neuroscience Lett., 1991, 121, 263; Murray et
al., Pain, 1991, 44, 179; and Woolf and Thompson, Pain,
1991, 44, 293) and anxiolytic (see, for example,

- 2 -

US-5145866; and Kehne et al., Eur. J. Pharmacol., 1991, 193, 283) effects, and the compounds of the present invention may accordingly be useful in the management of pain and anxiety.

5 Compounds possessing functional antagonist properties for the NMDA receptor complex are stated in WO-A-91/19493 to be effective in the treatment of mood disorders, including major depression, bipolar disorder, dysthymia and seasonal affective disorder (cf. also
10 Trullas and Skolnick, Eur. J. Pharmacol., 1990, 185, 1). The compounds of the present invention may consequently be of benefit in the treatment and/or prevention of such disorders.

15 The association of NMDA receptor antagonists with regulation of the dopaminergic system has recently been reported (see, for example, Werling et al., J. Pharmacol. Exp. Ther., 1990, 255, 40; Graham et al., Life Sciences, 1990, 47, PL-41; Hutson et al., Br. J. Pharmacol., 1991, 103, 2037; and Turski et al., Nature
20 (London), 1991, 349, 414). This suggests that the compounds of the present invention may thus be of assistance in the prevention and/or treatment of disorders of the dopaminergic system such as schizophrenia and Parkinson's disease.

25 It has also been reported recently (see Lauritzen et al., Journal of Cerebral Blood Flow and Metabolism, 1991, vol. 11, suppl. 2, Abstract XV-4) that NMDA receptor antagonists block cortical spreading depression (CSD), which may thus be of clinical
30 importance since CSD is a possible mechanism of migraine. The class of substituted 2-amino-4-phosphonomethylalk-3-ene carboxylic acids and esters described in EP-A-0420806, which are stated to be selective NMDA

- 3 -

antagonists, are alleged thereby to be of potential utility in the treatment of inter alia migraine.

Excitatory amino acid receptor antagonists, including inter alia antagonists of NMDA receptors, are
5 alleged in EP-A-0432994 to be of use in suppressing emesis.

Recent reports in the literature have also suggested a link between the neurotoxicity of certain viruses and the deleterious effects of these viruses on
10 an organism caused by the potentiation of neurotransmission via excitatory amino acid receptors. By virtue of their activity as antagonists of NMDA receptors, therefore, the compounds of the present invention may be effective in controlling the
15 manifestations of neuroviral diseases such as measles, rabies, tetanus (cf. Bagetta et al., Br. J. Pharmacol., 1990, 101, 776) and AIDS (cf. Lipton et al., Society for Neuroscience Abstracts, 1990, 16, 128.11).

NMDA antagonists have, moreover, been shown to
20 have an effect on the neuroendocrine system (see, for example, van den Pol et al., Science, 1990, 250, 1276; and Urbanski, Endocrinology, 1990, 127, 2223), and the compounds of this invention may therefore also be effective in the control of seasonal breeding in mammals.

25 In addition, certain compounds of the invention are antagonists of 2-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, also known as quisqualate receptors. An excitatory amino acid projection from the prefrontal cortex to the nucleus
30 accumbens (a particular region of the forebrain possessing dopamine-sensitive neurones) is well known to exist (see, for example, J. Neurochem., 1985, 45, 477). It is also well known that dopaminergic transmission in the striatum is modulated by glutamate (see, for example,

- 4 -

Neurochem. Int., 1983, 5, 479), as also is the hyperactivity associated with presynaptic stimulation of the dopamine system by AMPA in the nucleus accumbens (cf. Life Sci., 1981, 28, 1597). Compounds which are
5 antagonists of AMPA receptors are therefore of value as neuroleptic agents.

A class of 3-phenyl-2(1H)-quinolone derivatives, substituted at the 4-position by an unsubstituted straight or branched alkoxy group
10 containing 1 to 4 carbon atoms and at the 7-position by an unsubstituted straight or branched alkoxy group containing 2 to 10 carbon atoms or by a straight or branched alkoxy group containing 1 to 6 carbon atoms having at least one substituent selected from hydroxy,
15 carboxy and carbamoyl, is described in JP-A-63-295561. These compounds are stated therein to exhibit a strong inhibitory action on bone resorption and a stimulatory effect on ossification, and thus to be useful as therapeutic agents for the prevention and treatment of
20 osteoporosis.

A range of 3-(2-methoxyphenyl)-2(1H)-quinolones, possessing a halogen substituent in the 6- or 7-position and an optional carboxylic acid substituent at the 4-position, is described in J. Heterocycl. Chem.,
25 1989, 26, 281. The compound 4-carboxy-6-iodo-3-phenyl-2(1H)-quinolone is disclosed in J. Chem. Soc., 1929, 2911.


A family of 3-phenyl-2(1H)-quinolone derivatives, substituted at the 4-position by an amino or
30 benzylamino group and at the 7-position by a methyl or methoxy group, is described in Monatsh. Chem., 1982, 113, 751; and Vestn. Slov. Kem. Drus., 1986, 33, 271.

Except for JP-A-63-295561 as mentioned above, none of the aforementioned publications discloses any

- 5 -

therapeutic utility for the various 3-phenyl-2(1H)-quinolone derivatives described therein. Moreover, in none of the prior art documents is there any suggestion that the compounds described therein would be of assistance in solving the problem of providing an effective agent for the treatment and/or prevention of conditions requiring the administration of an antagonist of NMDA and/or AMPA receptors.

The present invention accordingly provides the use of a compound of formula I or a pharmaceutically acceptable salt thereof or a prodrug thereof:



(I)

wherein

R represents a hydrogen atom, an amino group, a carboxy or C₂₋₆ alkoxy carbonyl group, or a group of formula -A-B-E, in which

A represents a chemical bond, an oxygen or sulphur atom, or an -NH- group;

B represents a carbonyl (C=O) or sulphonyl (SO₂) group, or a straight or branched alkylene chain containing from 1 to 6 carbon atoms; and

E represents C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, cyano, phenyl, tetrazolyl, methyloxadiazolyl, -NR^aR^b, -COR^a, -C(=N. OR^a)R^b, -CO₂R^a, -CONR^aR^b, -CONR^a.OR^b or -CH₂CO₂R^a;

- 6 -

R¹ and R² independently represent hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, -OR^a, -SR^a, -SOR^a, -SO₂R^a, -SO₂NR^aR^b, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -COR^a, -CO₂R^a or -CONR^aR^b; or R¹ and R² together represent the residue of a carbocyclic or heterocyclic ring;

one of R³, R⁴, R⁵ and R⁶ represents hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, -OR^a, -SR^a, -SOR^a, -SO₂R^a, -SO₂NR^aR^b, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -COR^a, -CO₂R^a or -CONR^aR^b, and the other three of R³, R⁴, R⁵ and R⁶ independently represent hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, -OR^a, -SR^a, -SOR^a, -SO₂R^a, -SO₂NR^aR^b, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -COR^a, -CO₂R^a or -CONR^aR^b; and

R^a and R^b independently represent hydrogen, hydrocarbon or a heterocyclic group; for the manufacture of a medicament for the treatment and/or prevention of conditions, in particular neurodegenerative disorders, which require the administration of a selective non-competitive antagonist of NMDA receptors.

The present invention further provides the use of a compound of formula I as defined above or a pharmaceutically acceptable salt thereof or a prodrug thereof for the manufacture of a medicament for the treatment and/or prevention of conditions, such as schizophrenia, which require the administration of an antagonist of AMPA receptors.

The compounds of use in the present invention include those wherein E represents C₁₋₆ alkyl, C₂₋₆ alkenyl, phenyl, -NR^aR^b, -CO₂R^a or -CH₂CO₂R^a; and the remaining substituents are as defined with reference to formula I above.

- 7 -

The compounds of formula I can exist as alternative tautomeric forms. It is to be understood that all tautomeric forms of the compounds of formula I, as well as all possible mixtures thereof, are included within the scope of the present invention.

The term "hydrocarbon" as used herein includes straight-chained, branched and cyclic groups containing up to 18 carbon atoms, suitably up to 15 carbon atoms, and conveniently up to 12 carbon atoms. Suitable hydrocarbon groups include C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl(C₁₋₆)alkyl, aryl, aryl(C₁₋₆)alkyl, aryl(C₂₋₆)alkenyl and aryl(C₂₋₆)alkynyl.

The expression "a heterocyclic group" as used herein includes cyclic groups containing up to 18 carbon atoms and at least one heteroatom preferably selected from oxygen, nitrogen and sulphur. The heterocyclic group suitably contains up to 15 carbon atoms and conveniently up to 12 carbon atoms, and is preferably linked through carbon. Examples of suitable heterocyclic groups include C₃₋₇ heterocycloalkyl, C₃₋₇ heterocycloalkyl(C₁₋₆)alkyl, heteroaryl and heteroaryl(C₁₋₆)alkyl groups.

Suitable alkyl groups include straight-chained and branched alkyl groups containing from 1 to 6 carbon atoms. Typical examples include methyl and ethyl groups, and straight-chained or branched propyl and butyl groups. Particular alkyl groups are methyl, ethyl and t-butyl.

Suitable alkenyl groups include straight-chained and branched alkenyl groups containing from 2 to 6 carbon atoms. Typical examples include vinyl and allyl groups.

Suitable alkynyl groups include straight-chained and branched alkynyl groups containing from 2 to

- 8 -

6 carbon atoms. Typical examples include ethynyl and propargyl groups.

Suitable cycloalkyl groups include groups containing from 3 to 7 carbon atoms. Particular cycloalkyl groups are cyclopropyl and cyclohexyl.

Suitable aryl groups include phenyl and naphthyl groups.

A particular aryl(C₁₋₆)alkyl group is benzyl.

A particular aryl(C₂₋₆)alkenyl group is phenylethenyl.

A particular aryl(C₂₋₆)alkynyl group is phenylethynyl.

Suitable heterocycloalkyl groups include piperidyl, piperazinyl and morpholinyl groups.

A particular heterocycloalkyl(C₁₋₆)alkyl group is morpholinylethyl.

Suitable heteroaryl groups include pyridyl, quinolyl, isoquinolyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolyl, indolyl, pyranal, furyl, benzofuryl, thienyl, benzthienyl, imidazolyl, oxadiazolyl and thiadiazolyl groups. Particular heteroaryl groups are pyridyl, pyrrolyl, indolyl, furyl, benzofuryl, thienyl, benzthienyl and oxadiazolyl.

Particular heteroaryl(C₁₋₆)alkyl groups include pyridylmethyl, pyrrolylmethyl, indolylmethyl, furylmethyl and thienylmethyl.

Where R¹ and R² together represent the residue of a carbocyclic or heterocyclic ring, the ring may be saturated or unsaturated. The ring may suitably be a 4- to 9-membered ring, but will preferably be a 5- or 6-membered ring. Where R¹ and R² together represent the residue of a heterocyclic ring, this ring may contain up to four heteroatoms selected from oxygen, nitrogen and sulphur. Suitable carbocyclic rings of which R¹ and R²

- 9 -

together represent the residue include cyclohexane, cyclohexene, cyclohexadiene and benzene rings. Suitable heterocyclic rings of which R¹ and R² together represent the residue include dioxolane, dioxane, pyridine, furan, thiophene, pyrrole, thiazole and thiadiazole rings.

The hydrocarbon and heterocyclic groups, as well as the carbocyclic or heterocyclic ring completed by R¹ and R², may in turn be optionally substituted by one or more groups selected from C₁₋₆ alkyl, adamantyl, phenyl, halogen, C₁₋₆ haloalkyl, morpholinyl(C₁₋₆)alkyl, trifluoromethyl, hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkoxy(C₁₋₆)alkyl, C₁₋₆ alkoxy(C₁₋₆)alkoxy, aryloxy, keto, C₁₋₃ alkylenedioxy, nitro, cyano, carboxy, C₂₋₆ alkoxycarbonyl, C₂₋₆ alkoxycarbonyl(C₁₋₆)alkyl, C₂₋₆ alkylcarbonyloxy, arylcarbonyloxy, C₂₋₆ alkylcarbonyl, arylcarbonyl, C₁₋₆ alkylthio, C₁₋₆ alkylsulphinyl, C₁₋₆ alkylsulphonyl, amino, mono- or di(C₁₋₆)alkylamino, C₂₋₆ alkylcarbonylamino and C₂₋₆ alkoxycarbonylamino.

The term "halogen" as used herein includes fluorine, chlorine, bromine and iodine, especially chlorine.

When R in the compounds of formula I above represents a group of formula -A-B-E, and B represents a straight or branched alkylene chain containing from 1 to 6 carbon atoms, this alkylene chain may be, for example, methylene, ethylene, 1-methylethylene, propylene or 2-methylpropylene, preferably methylene, ethylene or propylene.

Examples of suitable substituents represented by the group R include hydrogen, carboxy(C₁₋₆)alkoxy, C₂₋₆ alkoxycarbonyl(C₁₋₆)alkoxy, C₃₋₁₀ alkenyloxy, C₂₋₆ alkynyloxy, cyano(C₁₋₆)alkoxy, amino(C₁₋₆)alkoxy, di(C₁₋₆)alkylamino(C₁₋₆)alkoxy, C₁₋₆ alkanoyl(C₁₋₆)alkoxy, oximino(C₁₋₆)alkoxy, C₁₋₆ alkyloximino(C₁₋₆)alkoxy,

- 10 -

aminocarbonyl(C₁₋₆)alkoxy, di(C₁₋₆)aminocarbonyl(C₁₋₆)alkoxy,
C₁₋₆ alkoxyaminocarbonyl(C₁₋₆)alkoxy, amino,
phenyl(C₁₋₆)alkylamino, amino(C₁₋₆)alkylamino,
di(C₁₋₆)alkylamino(C₁₋₆)alkylamino, carboxy(C₁₋₆)alkylamino,
5 C₂₋₆ alkanoylamino, carboxy-carbonylamino, C₂₋₆
alkoxycarbonyl-carbonylamino, carboxymethyl-
carbonylamino, C₂₋₆ alkoxycarbonylmethyl-carbonylamino,
C₁₋₆ alkylsulphonylamino, phenylsulphonylamino, carboxy,
C₂₋₆ alkoxycarbonyl, carboxy(C₁₋₆)alkyl, C₂₋₆
10 alkoxycarbonyl(C₁₋₆)alkyl, cyano(C₁₋₆)alkyl,
tetrazolyl(C₁₋₆)alkyl, methyloxadiazolyl(C₁₋₆)alkyl and
aminocarbonyl(C₁₋₆)alkyl.

Particular examples of the substituent R
include hydrogen, carboxy-methoxy, methoxycarbonyl-
15 methoxy, allyloxy, propynyloxy, cyano-methoxy,
dimethylamino-ethoxy, methylcarbonyl-methoxy, oximino-
propyloxy, methyloximino-propyloxy, aminocarbonyl-
methoxy, dimethylaminocarbonyl-methoxy,
methoxyaminocarbonyl-methoxy, amino, benzylamino,
20 dimethylamino-ethylamino, dimethylamino-propylamino,
acetylamino, carboxymethyl-carbonylamino, carboxy-
carbonylamino, methoxycarbonyl-carbonylamino,
methylsulphonylamino, phenylsulphonylamino, carboxy,
methoxycarbonyl, carboxymethyl, methoxycarbonyl-methyl,
25 carboxyethyl, methoxycarbonyl-ethyl, cyanoethyl,
tetrazolyl-ethyl, methyloxadiazolyl-ethyl and
aminocarbonyl-ethyl.

Suitable values for the substituents R¹ and R²
include C₁₋₆ alkyl, aryl, aryl(C₁₋₆)alkyl, aryl(C₂₋₆)alkenyl,
30 aryl(C₂₋₆)alkynyl, heteroaryl(C₁₋₆)alkyl, C₁₋₆ alkoxy, C₂₋₆
alkenyloxy, aryloxy, aryl(C₁₋₆)alkoxy, heteroaryloxy,
arylthio, arylsulphonyl, arylamino, aryl(C₁₋₆)alkylamino,
di(C₁₋₆)alkylamino, arylcarbonylamino, arylcarbonyl or
heteroarylcarbonyl, any of which groups may be optionally

- 11 -

substituted; and hydrogen, halogen, trifluoromethyl, nitro, hydroxy or carboxy. Examples of optional substituents on the groups R¹ and/or R² include C₁₋₆ alkyl, morpholinyl(C₁₋₆)alkyl, hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkoxy(C₁₋₆)alkyl, C₁₋₆ alkoxy(C₁₋₆)alkoxy, C₁₋₆ alkylthio and di(C₁₋₆)alkylamino.

Particular values for the substituents R¹ and R² include hydrogen, methyl, phenyl, benzyl, methoxymethyl-benzyl, morpholinylethyl-benzyl, hydroxybenzyl, methoxybenzyl, methoxymethoxy-benzyl, methylthio-benzyl, phenylethenyl, phenylethynyl, thienylmethyl, pyrrolylmethyl, indolylmethyl, fluoro, chloro, bromo, iodo, trifluoromethyl, nitro, hydroxy, methoxy, ethoxy, allyloxy, methyl-allyloxy, phenoxy, methyl-phenoxy, methoxy-phenoxy, dimethylamino-phenoxy, benzyloxy, furyloxy, thienyloxy, pyridyloxy, phenylthio, phenylsulphonyl, amino, phenylamino, benzylamino, dimethylamino, phenylcarbonylamino, phenylcarbonyl, furylcarbonyl, thienylcarbonyl and carboxy, especially hydroxy, methoxy, phenoxy, amino and carboxy.

Suitably, one of R¹ and R² represents hydrogen. Preferably, at least one of R¹ and R² is other than hydrogen.


Where R¹ and R² together represent the residue of a carbocyclic or heterocyclic ring, this may be, in particular, a dioxolane or optionally substituted benzene ring.

The benzo moiety of the 2(1H)-quinolone ring system shown in formula I above contains at least one non-hydrogen substituent. Particular substituents include halogen, cyano, trifluoromethyl, nitro, hydroxy, amino, carboxy, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio and C₂₋₇ alkoxycarbonyl. Suitably R⁶ is hydrogen and R³, R⁴ and R⁵ independently represent hydrogen,

- 12 -

halogen, cyano, trifluoromethyl, nitro, C₁₋₆ alkyl or C₂₋₆ alkenyl, provided that at least one of R³, R⁴ and R⁵ is other than hydrogen. Preferably, R⁴ and R⁶ each represents hydrogen, one of R³ and R⁵ represents cyano, trifluoromethyl, nitro, methyl, ethyl, vinyl or halogen, especially chlorine or iodine, and the other of R³ and R⁵ represents hydrogen, cyano, trifluoromethyl, nitro, methyl, ethyl, vinyl or halogen, especially chlorine or iodine. In a particular embodiment, R⁵ represents cyano, trifluoromethyl, nitro or halogen, especially chlorine; and R³ is hydrogen or ethyl.

In a further aspect, the invention provides a pharmaceutical composition comprising a compound of formula IA or a pharmaceutically acceptable salt thereof or a prodrug thereof:



(IA)

wherein

R¹⁰ represents a hydrogen atom, an amino group, a carboxy or C₂₋₆ alkoxy carbonyl group, or a group of formula -A-B-E, in which

A represents a chemical bond, an oxygen or sulphur atom, or an -NH- group;

B represents a carbonyl (C=O) or sulphonyl (SO₂) group, or a straight or branched alkylene chain containing from 1 to 6 carbon atoms; and

- 13 -

E represents C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, cyano, phenyl, tetrazolyl, methyloxadiazolyl, -NR^aR^b, -COR^a, -C(=N. OR^a)R^b, -CO₂R^a, -CONR^aR^b, -CONR^a.OR^b or -CH₂CO₂R^a;

5 R¹¹ and R¹² independently represent hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, -OR^a, -SR^a, -SOR^a, -SO₂R^a, -SO₂NR^aR^b, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -COR^a, -CO₂R^a or -CONR^aR^b; or R¹¹ and R¹² together represent the residue of
10 a carbocyclic or heterocyclic ring;

one of R¹³, R¹⁴, R¹⁵ and R¹⁶ represents hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, -OR^a, -SR^a, -SOR^a, -SO₂R^a, -SO₂NR^aR^b, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -COR^a, -CO₂R^a or
15 -CONR^aR^b, and the other three of R¹³, R¹⁴, R¹⁵ and R¹⁶ independently represent hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, -OR^a, -SR^a, -SOR^a, -SO₂R^a, -SO₂NR^aR^b, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -COR^a, -CO₂R^a or -CONR^aR^b; and

20 R^a and R^b independently represent hydrogen, hydrocarbon or a heterocyclic group;

provided that, when R¹⁰ represents a straight or branched alkoxy group containing 2 to 4 carbon atoms and R¹¹, R¹², R¹³, R¹⁴ and R¹⁶ each represents hydrogen, then R¹⁵
25 does not represent an unsubstituted straight or branched alkoxy group containing 2 to 10 carbon atoms or a straight or branched alkoxy group containing 1 to 6 carbon atoms having at least one substituent selected from hydroxy, carboxy and carbamoyl;
30 in association with one or more pharmaceutically acceptable carriers and/or excipients.

The invention also provides a compound of formula IA as defined above or a pharmaceutically


- 14 -

acceptable salt thereof or a prodrug thereof for use in therapy.

Subject to the above proviso, the substituents R^{10} and R^{11} to R^{16} in the compounds of formula IA correspond to the substituents R and R^1 to R^6 respectively as defined with reference to the compounds of formula I.

Particular pharmaceutical compositions according to the invention contain, as the active ingredient, at least one of the following compounds:
 7-chloro-3-(2-methoxyphenyl)-2(1H)-quinolone;
 and pharmaceutically acceptable salts thereof and prodrugs thereof.

Certain compounds falling within the definition of formula I above are novel. Accordingly, in a still further aspect the present invention provides a compound of formula IB or a salt or prodrug thereof:



(IB)

wherein

R^{20} represents a hydrogen atom, an amino group, a carboxy or C₂₋₆ alkoxy carbonyl group, or a group of formula -A-B-E, in which

A represents a chemical bond, an oxygen or sulphur atom, or an -NH- group;

- 15 -

B represents a carbonyl (C=O) or sulphonyl (SO₂) group, or a straight or branched alkylene chain containing from 1 to 6 carbon atoms; and

E represents C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, cyano, phenyl, tetrazolyl, methyloxadiazolyl, 5 -NR^aR^b, -COR^a, -C(=N.OR^a)R^b, -CO₂R^a, -CONR^aR^b, -CONR^a.OR^b or -CH₂CO₂R^a;

R²¹ and R²² independently represent hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, 10 trifluoromethyl, nitro, -OR^a, -SR^a, -SOR^a, -SO₂R^a, -SO₂NR^aR^b, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -COR^a, -CO₂R^a or -CONR^aR^b; or R²¹ and R²² together represent the residue of a carbocyclic or heterocyclic ring;

one of R²³, R²⁴, R²⁵ and R²⁶ represents 15 hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, -OR^a, -SR^a, -SOR^a, -SO₂R^a, -SO₂NR^aR^b, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -COR^a, -CO₂R^a or -CONR^aR^b, and the other three of R²³, R²⁴, R²⁵ and R²⁶ independently represent hydrogen, hydrocarbon, a 20 heterocyclic group, halogen, cyano, trifluoromethyl, nitro, -OR^a, -SR^a, -SOR^a, -SO₂R^a, -SO₂NR^aR^b, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -COR^a, -CO₂R^a or -CONR^aR^b; and

R^a and R^b independently represent hydrogen, hydrocarbon or a heterocyclic group;

25 provided that, when R²¹ and R²² each represents hydrogen, then:

(i) R²⁵ does not represent an unsubstituted straight or branched alkoxy group containing 2 to 10 carbon atoms or a straight or branched alkoxy group 30 containing 1 to 6 carbon atoms having at least one substituent selected from hydroxy, carboxy and carbamoyl when R²⁰ represents a straight or branched alkoxy group containing 2 to 4 carbon atoms and R²³, R²⁴ and R²⁶ each represents hydrogen; and

- 16 -

(ii) R^{20} does not represent carboxy when R^{24} is iodo and R^{23} , R^{25} and R^{26} each represents hydrogen; and

(iii) R^{20} does not represent amino or benzylamino when R^{25} represents methyl or methoxy and R^{23} , R^{24} and R^{26} each represent hydrogen;

provided also that when R^{21} is 2'-methoxy and R^{22} , R^{23} and R^{26} each represents hydrogen, then:

(i) R^{20} does not represent hydrogen or carboxy when one of R^{24} and R^{25} represents fluoro or chloro and the other is hydrogen; and

(ii) R^{20} does not represent carboxy when one of R^{24} and R^{25} represents bromo or iodo and other is hydrogen.

Subject to the above provisos, the substituents R^{20} and R^{21} to R^{26} in the compounds of formula IB correspond to the substituents R and R^1 to R^6 respectively as defined with reference to the compounds of formula I.

For use in medicine, the salts of the compounds of formula IB will be non-toxic pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds according to the invention or of their non-toxic pharmaceutically acceptable salts.

Suitable pharmaceutically acceptable salts of the compounds of formulae I, IA and IB above include alkali metal salts, e.g. lithium, sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts. Where appropriate, acid addition salts may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable non-toxic acid such as hydrochloric acid, sulphuric acid, fumaric acid, maleic acid, succinic acid,

- 17 -

acetic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.

The present invention includes within its scope prodrugs of the compounds of formulae I, IA and IB above.

5 In general, such prodrugs will be functional derivatives of the compounds of formulae I, IA and IB which are readily convertible in vivo into the required compound. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for
10 example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.


Where the compounds according to the invention have at least one asymmetric centre, they may accordingly exist as enantiomers. Where the compounds according to
15 the invention possess two or more asymmetric centres, they may additionally exist as diastereoisomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.

20 One sub-class of compounds according to the invention is represented by the compounds of formula IIA and salts and prodrugs thereof:

25

30

- 18 -



(11A)

wherein

R^{31} represents C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, aryl(C_{1-6})alkyl, aryl(C_{2-6})alkenyl, aryl(C_{2-6})alkynyl, heteroaryl(C_{1-6})alkyl, C_{1-6} alkoxy, C_{2-6} alkenyloxy, aryloxy, aryl(C_{1-6})alkoxy, heteroaryloxy, C_{1-6} alkylthio, arylthio, arylsulphonyl, arylamino, aryl(C_{1-6})alkylamino, di(C_{1-6})alkylamino, arylcarbonylamino, arylcarbonyl, heteroarylcarbonyl or C_{2-7} alkoxy carbonyl, any of which groups may be optionally substituted; or hydrogen, halogen, cyano, trifluoromethyl, nitro, hydroxy, amino or carboxy; and

R^{32} represents C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, aryl(C_{1-6})alkyl, aryl(C_{2-6})alkenyl, aryl(C_{2-6})alkynyl, heteroaryl(C_{1-6})alkyl, C_{2-6} alkoxy, C_{2-6} alkenyloxy, aryloxy, aryl(C_{1-6})alkoxy, heteroaryloxy, C_{1-6} alkylthio, arylthio, arylsulphonyl, arylamino, aryl(C_{1-6})alkylamino, di(C_{1-6})alkylamino, arylcarbonylamino, arylcarbonyl, heteroarylcarbonyl or C_{2-7} alkoxy carbonyl, any of which groups may be optionally substituted; or halogen, cyano, trifluoromethyl, nitro, hydroxy, amino or carboxy; or

R^{31} and R^{32} together represent the residue of a carbocyclic or heterocyclic ring;

- 19 -

R³³ represents hydrogen, halogen, cyano, trifluoromethyl, nitro, hydroxy, amino, carboxy, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio or C₂₋₇ alkoxycarbonyl;

5 R³⁴ represents hydrogen or halogen; and
R³⁵ represents halogen, cyano, trifluoromethyl, nitro, hydroxy, amino, carboxy, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio or C₂₋₇ alkoxycarbonyl.

Examples of optional substituents on the groups
10 R³¹ and/or R³² include C₁₋₆ alkyl, morpholinyl(C₁₋₆)alkyl, hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkoxy(C₁₋₆)alkyl, C₁₋₆ alkoxy-(C₁₋₆)alkoxy, C₁₋₆ alkylthio and di(C₁₋₆)alkylamino.

Particular values of R³¹ with respect to formula IIA include hydrogen, hydroxy, methoxy, phenoxy, amino
15 and carboxy, preferably hydrogen or methoxy. Particular values of R³² with respect to formula IIA include hydroxy, phenoxy, amino and carboxy.

In an especial embodiment, R³¹ is hydrogen and R³² is hydroxy, amino or carboxy.

20 Suitably, R³³ represents hydrogen, nitro, methyl, ethyl, vinyl or halogen, especially chlorine or iodine. Preferably, R³³ is hydrogen, ethyl or iodine.


Suitably, R³⁴ represents hydrogen or chlorine, preferably hydrogen.

25 Suitably, R³⁵ represents cyano, trifluoromethyl, nitro, methyl or halogen, preferably chlorine.

Another sub-class of compounds according to the invention is represented by the compounds of formula IIB and salts and prodrugs thereof:

30

- 20 -



(IIB)

wherein

A¹ represents a chemical bond, an oxygen atom or an -NH- group;

15 B¹ represents a carbonyl (C=O) or sulphonyl (SO₂) group, or a group of formula -(CH₂)_n- in which n is 1, 2, 3 or 4; and

E¹ represents C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, cyano, phenyl, tetrazolyl, methyloxadiazolyl, amino, C₁₋₆ alkylamino, di(C₁₋₆)alkylamino, C₁₋₆ alkanoyl, 20 oximino(C₁₋₆)alkyl, C₁₋₆ alkyloximino(C₁₋₆)alkyl, carboxy, C₂₋₆ alkoxy carbonyl, aminocarbonyl, di(C₁₋₆)alkylaminocarbonyl, C₁₋₆ alkoxyaminocarbonyl, carboxymethyl or C₂₋₆ alkoxy carbonyl-methyl;

25 R⁴¹ and R⁴² independently represent C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, aryl(C₁₋₆)alkyl, aryl(C₂₋₆)alkenyl, aryl(C₂₋₆)alkynyl, heteroaryl(C₁₋₆)alkyl, C₁₋₆ alkoxy, C₂₋₆ alkenyloxy, aryloxy, aryl(C₁₋₆)alkoxy, heteroaryloxy, C₁₋₆ alkylthio, arylthio, arylsulphonyl, 30 arylamino, aryl(C₁₋₆)alkylamino, di(C₁₋₆)alkylamino, arylcarbonylamino, arylcarbonyl, heteroarylcarbonyl or C₂₋₇ alkoxy carbonyl, any of which groups may be optionally substituted; or hydrogen, halogen, cyano, trifluoromethyl, nitro, hydroxy, amino or carboxy; or

- 21 -

R⁴¹ and R⁴² together represent the residue of a carbocyclic or heterocyclic ring;

R⁴³ and R⁴⁴ independently represent hydrogen, halogen, cyano, trifluoromethyl, nitro, hydroxy, amino, carboxy, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio or C₂₋₇ alkoxycarbonyl; and

R⁴⁵ represents halogen, cyano, trifluoromethyl, nitro, hydroxy, amino, carboxy, C₂₋₆ alkenyl, C₁₋₆ alkylthio or C₂₋₇ alkoxycarbonyl.

Examples of optional substituents on the groups R⁴¹ and/or R⁴² include C₁₋₆ alkyl, morpholinyl(C₁₋₆)alkyl, hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkoxy(C₁₋₆)alkyl, C₁₋₆ alkoxy(C₁₋₆)alkoxy, C₁₋₆ alkylthio and di(C₁₋₆)alkylamino.

Particular examples of the substituent -A¹-B¹-E¹ with reference to formula IIB include carboxymethyl, methoxycarbonyl-methyl, carboxyethyl, methoxycarbonyl-ethyl, cyanoethyl, tetrazolyl-ethyl, methyloxadiazolyl-ethyl, aminocarbonyl-ethyl, carboxymethoxy, methoxycarbonyl-methoxy, allyloxy, propynyloxy, cyano-methoxy, dimethylamino-ethoxy, methylcarbonyl-methoxy, oximino-propyloxy, methyloximino-propyloxy, aminocarbonyl-methoxy, dimethylaminocarbonyl-methoxy, methoxyaminocarbonyl-methoxy, benzylamino, dimethylamino-ethylamino, dimethylamino-propylamino, acetylamino, carboxymethyl-carbonylamino, carboxy-carbonylamino, methoxycarbonyl-carbonylamino, methylsulphonylamino and phenylsulphonylamino.

Particular values of R⁴¹ and/or R⁴² with respect to formula IIB include hydrogen, methyl, phenyl, benzyl, methoxymethyl-benzyl, morpholinylethyl-benzyl, hydroxybenzyl, methoxybenzyl, methoxymethoxy-benzyl, methylthio-benzyl, phenylethenyl, phenylethynyl, thienylmethyl, pyrrolylmethyl, indolylmethyl, fluoro, chloro, bromo, iodo, trifluoromethyl, nitro, hydroxy,

- 22 -

methoxy, ethoxy, allyloxy, methyl-allyloxy, phenoxy,
methyl-phenoxy, methoxy-phenoxy, dimethylamino-phenoxy,
benzyloxy, furyloxy, thienyloxy, pyridyloxy, phenylthio,
phenylsulphonyl, amino, phenylamino, benzylamino,
5 dimethylamino, phenylcarbonylamino, phenylcarbonyl,
furylcarbonyl, thienylcarbonyl and carboxy. Moreover, R⁴¹
and R⁴² may suitably together represent the residue of a
dioxolane or optionally substituted benzene ring.

Preferably, one of R⁴¹ and R⁴² represents
10 hydrogen and the other represents hydrogen, hydroxy,
methoxy, phenoxy, amino or carboxy.

Suitably, R⁴³ and R⁴⁴ independently represent
hydrogen, nitro, methyl, ethyl, vinyl or halogen,
especially chlorine or iodine. Preferably, R⁴³ is
15 hydrogen, ethyl or iodine. Preferably, R⁴⁴ is hydrogen.

Suitably, R⁴⁵ represents cyano, trifluoromethyl,
nitro or halogen, preferably chlorine.

Specific compounds within the scope of the
present invention include:

20 7-chloro-3-(2-hydroxyphenyl)-2(1H)-quinolone;
7-chloro-3-(4-hydroxyphenyl)-2(1H)-quinolone;
3-(2-aminophenyl)-7-chloro-2(1H)-quinolone;
3-(3-carboxyphenyl)-7-chloro-2(1H)-quinolone;
4-carboxy-7-chloro-3-phenyl-2(1H)-quinolone;
25 4-carboxymethyl-7-chloro-3-phenyl-2(1H)-quinolone;
7-chloro-4-methoxycarbonylmethyl-3-phenyl-2(1H)-
quinolone;
4-carboxymethoxy-7-chloro-3-phenyl-2(1H)-quinolone;
7-chloro-4-methoxycarbonylmethoxy-3-phenyl-2(1H)-
30 quinolone;
4-allyloxy-7-chloro-3-phenyl-2(1H)-quinolone;
4-amino-7-chloro-3-phenyl-2(1H)-quinolone;
4-amino-7-chloro-3-(2-methoxyphenyl)-2(1H)-quinolone;
4-amino-7-chloro-3-(3-phenoxyphenyl)-2(1H)-quinolone;

- 23 -

- 4-benzylamino-7-chloro-3-phenyl-2(1H)-quinolone;
7-chloro-4-(2-dimethylaminoethyl)amino-3-phenyl-2(1H)-
quinolone;
7-chloro-4-(3-dimethylaminopropyl)amino-3-phenyl-2(1H)-
5 quinolone;
4-acetylamino-7-chloro-3-phenyl-2(1H)-quinolone;
4-carboxymethylcarbonylamino-7-chloro-3-phenyl-2(1H)-
quinolone;
4-carboxycarbonylamino-7-chloro-3-phenyl-2(1H)-quinolone;
10 7-chloro-4-methoxycarbonylcarbonylamino-3-phenyl-2(1H)-
quinolone;
7-chloro-4-methylsulphonylamino-3-phenyl-2(1H)-quinolone;
7-chloro-3-phenyl-4-phenylsulphonylamino-2(1H)-quinolone;
7-chloro-4-methylcarbonylmethoxy-3-phenyl-2(1H)-
15 quinolone;
7-chloro-4-(2-oximinopropyl)oxy-3-phenyl-2(1H)-quinolone;
7-chloro-3-phenyl-4-(2-propynyl)oxy-2(1H)-quinolone;
7-chloro-4-(2-methyloximinopropyl)oxy-3-phenyl-2(1H)-
quinolone;
20 7-chloro-4-methoxycarbonylmethoxy-3-(3-phenoxyphenyl)-
2(1H)-quinolone;
4-carboxymethoxy-7-chloro-3-(3-phenoxyphenyl)-2(1H)-
quinolone;
7-chloro-4-cyanomethoxy-3-phenyl-2(1H)-quinolone;
25 7-chloro-4-cyanomethoxy-3-(3-phenoxyphenyl)-2(1H)-
quinolone;
7-chloro-4-(N,N-dimethylaminocarbonyl)methoxy-3-phenyl-
2(1H)-quinolone;
7-chloro-4-[2-(N,N-dimethylamino)ethoxy]-3-phenyl-2(1H)-
30 quinolone;
4-aminocarbonylmethoxy-7-chloro-3-phenyl-2(1H)-quinolone;
7-chloro-4-methoxyaminocarbonylmethoxy-3-phenyl-2(1H)-
quinolone;

- 24 -

7-chloro-4-(2-methoxycarbonyl-ethyl)-3-phenyl-2(1H)-quinolone;
4-(2-carboxyethyl)-7-chloro-3-phenyl-2(1H)-quinolone;
4-(2-aminocarbonyl-ethyl)-7-chloro-3-phenyl-2(1H)-
5 quinolone;
7-chloro-4-(2-cyanoethyl)-3-phenyl-2(1H)-quinolone;
7-chloro-3-phenyl-4-[2-(1H-tetrazol-5-yl)ethyl]-2(1H)-quinolone;
7-chloro-4-[2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-3-
10 phenyl-2(1H)-quinolone;
and salts and prodrugs thereof.

The pharmaceutical compositions of this invention are preferably in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile
15 solutions or suspensions, or suppositories, for oral, intravenous, parenteral or rectal administration. Alternatively, the composition may be presented in a form suitable for once-weekly or once-monthly administration; for example, an insoluble salt of the active compound,
20 such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting
25 ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a
30 compound of the present invention, or a non-toxic pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be

- 25 -

readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from
5 0.1 to about 500 mg of the active ingredient of the present invention. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can
10 comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass
15 intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose
20 acetate.

The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil
25 suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums
30 such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone or gelatin.

In the treatment of neurodegeneration, a suitable dosage level is about 0.01 to 250 mg/kg per day,


- 26 -

preferably about 0.05 to 100 mg/kg per day, and especially about 0.05 to 5 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day. In a particular embodiment, the compounds may be

5 conveniently administered by intravenous infusion.

The compounds of formula I above wherein R represents hydrogen, amino or a group of formula -A-B-E in which A represents a chemical bond and B is a straight or branched alkylene chain containing from 1 to 6 carbon

10 atoms, including the novel compounds according to the invention, may be prepared by a process which comprises cyclising a compound of formula III:



(III)

wherein R¹, R², R³, R⁴, R⁵ and R⁶ are as defined above; and G¹ represents an aldehyde (-CHO) or cyano (-CN) group, or

25 a group of formula -CO-B^a-E in which B^a represents a straight or branched alkylene chain containing from 1 to 6 carbon atoms and E is as defined above.

The reaction is conveniently carried out in the presence of a base, followed by a mild acidic work-up.


30 Suitable bases of use in the reaction include sodium methoxide, sodium hydride and potassium hexamethyldisilazide.

When G¹ in the compounds of formula III above represents an aldehyde group, the product of the reaction

- 27 -

is a compound of formula I wherein R is hydrogen. When G¹ represents a cyano group, the product of the reaction is a compound of formula I wherein R is an amino group. When G¹ represents a group of formula -CO-B^a-E, the product of the reaction is a compound of formula I wherein R is a group of formula -A-B-E in which A represents a chemical bond and B is a straight or branched alkylene group containing from 1 to 6 carbon atoms.

The compounds of formula I wherein R represents a group of formula -A-B-E in which A represents a chemical bond, B is a methylene group and E represents -CO₂R^a may be prepared by intramolecular Michael cyclisation of a compound of formula IIIA:




(IIIA)


wherein R¹, R², R³, R⁴, R⁵, R⁶ and R^a are as defined above; in the presence of a strong base, e.g. sodium methoxide; followed by quenching with a selenyl halide reagent, e.g. phenylselenenyl chloride; and subsequent elimination of selenium to afford the double bond in the 3,4-position.

The intermediates of formulae III and IIIA above may conveniently be prepared by reacting a compound of formula IV with a compound of formula V:

- 28 -



(IV)



(V)

wherein R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are as defined above; G^2 corresponds to the group G^1 as defined above or represents a group of formula $-\text{CH}=\text{CH}.\text{CO}_2\text{R}^a$ in which R^a is as defined above; and Q^1 represents a reactive carboxylate moiety.


The reaction is conveniently effected by mixing the reagents in an inert solvent, such as dichloromethane or 1,2-dichloroethane, and heating the reaction mixture at an elevated temperature, for example the reflux temperature of the solvent employed.

Suitable values for the reactive carboxylate moiety Q^1 include esters, for example C_{1-4} alkyl esters; acid anhydrides, for example mixed anhydrides with C_{1-4} alkanolic acids; acid halides, for example acid chlorides; orthoesters; and primary, secondary and tertiary amides.


Preferably, the group Q^1 is an acid halide group, in particular an acid chloride group. A compound of formula V wherein Q^1 represents an acid chloride group may conveniently be prepared from the corresponding compound of formula V wherein Q^1 represents a carboxy group $-\text{CO}_2\text{H}$ (i.e. a compound of formula VA as defined below) by treatment with oxalyl chloride or thionyl chloride under standard conditions well known from the art.

- 29 -

The compounds of formula I wherein R represents a carboxy group, including the novel compounds according to the invention, may be prepared by a process which comprises reacting a compound of formula VI with a
 5 compound of formula VA:



(VI)



(VA)


wherein R¹, R², R³, R⁴, R⁵ and R⁶ are as defined above.

The reaction is conveniently carried out in the presence of sodium acetate at an elevated temperature, e.g. 200 to 230°C, as described, for example, in J.

20 Heterocycl. Chem., 1989, 26, 281.

The compounds of formula I wherein R represents a group of formula -A-B-E in which A represents an oxygen or sulphur atom or an -NH- group, including the novel compounds according to the invention, may be prepared by
 25 reacting a compound of formula L-B-E with a compound of formula VII:

- 30 -



(VII)

wherein R¹, R², R³, R⁴, R⁵, R⁶, B and E are as defined above; A¹⁰ represents an oxygen or sulphur atom or an -NH- group; and L represents a leaving group such as a halogen atom, e.g. chloro or bromo.

15 The reaction is conveniently carried out in the presence of a base. When A¹⁰ represents oxygen or sulphur, a mild base such as sodium bicarbonate is advantageously employed, and the reaction is suitably effected in a solvent such as N,N-dimethylformamide.

20 When A¹⁰ represents an -NH- group, a preferred base, depending upon the nature of the reagent L-B-E, is sodium hydride or potassium hexamethyldisilazide, and the reaction is advantageously effected in a compatible solvent, such as tetrahydrofuran.

25 In an alternative process, the compounds of formula I wherein R represents a group of formula -A-B-E in which A represents an -NH- group, including the novel compounds according to the invention, may be prepared by reacting a compound of formula H₂N-B-E, wherein B and E are as defined above, with a compound of formula VII

30 above wherein A¹⁰ represents an oxygen atom.

The reaction is conveniently effected by heating the reagents together at the reflux temperature of the mixture, as described, for example, in Vestn.

- 31 -

Slov. Kem. Drus., 1986, 33, 271; or, if necessary, by maintaining the reaction mixture at an elevated temperature for several days in a sealed tube.

5 A given intermediate of formula VII above wherein A¹⁰ represents sulphur may be prepared from the corresponding compound of formula VII wherein A¹⁰ represents oxygen by treating the latter compound firstly with N,N-dimethylthiocarbamyl chloride and then with a mineral acid such as hydrochloric acid, followed by
10 hydrolysis with base, e.g. sodium hydroxide, by analogy with the procedure described in WO-A-91/01973.

The intermediates of formula VII above wherein A¹⁰ represents oxygen may be prepared by the procedures described in EP-A-0481676, or by methods analogous
15 thereto. Additional sources of reference for preparing compounds corresponding to those of formula VII above wherein A¹⁰ represents oxygen include, for example, J. Heterocycl. Chem., 1975, 12, 351; and ibid., 1988, 25, 857.

20 The aromatic intermediates of formulae IV, V, VA and VI above, where they are not commercially available, may be prepared by the methods described in the accompanying Examples, or by methods analogous thereto which will be readily apparent to those skilled
25 in the art.

As will be appreciated, the compounds of formula VII above wherein A¹⁰ represents an -NH- group, which can be used as intermediates in the preparation of compounds in accordance with the present invention, are
30 themselves compounds according to the invention. It is to be understood that any compound of formula I, IA or IB initially obtained from any of the above processes may, where appropriate, subsequently be elaborated into a further desired compound of formula I, IA or IB

- 32 -

respectively using techniques known from the art. For example, a compound of formula I initially obtained wherein R is carboxy may be converted into a corresponding compound of formula I wherein R represents a C₁₋₆ alkoxy carbonyl group by standard esterification procedures common in the art.

Where the above-described processes for the preparation of the compounds according to the invention give rise to mixtures of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The compounds may, for example, be resolved into their component enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-l-tartaric acid followed by fractional crystallization and regeneration of the free base. The compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary.

During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

- 33 -

The following Examples illustrate the preparation of compounds according to the invention.

The compounds useful in this invention potentially and selectively block responses to NMDA and/or AMPA in a brain slice from rat cortex, and inhibit the binding of agonists and antagonists to the strychnine-insensitive site present on the NMDA receptor and/or AMPA binding to rat forebrain membranes.

10 Cortical Slice Studies

The effects of compounds of the invention on responses to NMDA and AMPA were assessed using the rat cortical slice as described by Wong *et al.*, Proc. Natl. Acad. Sci. USA, 1986, 83, 7104. The apparent equilibrium constant (K_b) was calculated from the righthand shift in the NMDA or AMPA concentration-response curves produced by the compound under test. Of those compounds of the accompanying Examples which were tested, all were found to possess a K_b value in response to NMDA of below 150 μ M.

Binding Studies

The ability of test compounds to displace 3 H-L-689,560 (trans-2-carboxy-5,7-dichloro-4-phenyl-aminocarbonylamino-1,2,3,4-tetrahydroquinoline) binding to the strychnine-insensitive glycine site present on the NMDA receptor of rat forebrain membranes was determined by the method of Grimwood *et al.*, Proceedings of The British Pharmacological Society, July 1991, Abstract C78. The concentration of the compounds of the accompanying Examples required to displace 50% of the specific binding (IC_{50}) is below 50 μ M in each case.

- 34 -

EXAMPLE 14-Amino-7-chloro-3-(2-methoxyphenyl)-2(1H)-quinolone

5 5-Chloro-methyl anthranilate (20g) and 300ml of methanol saturated with ammonia were heated in an autoclave for 3 days at 150°C and the solvent was allowed to evaporate for 14h. The solid residue was triturated with diethyl ether and filtered. The brown solid obtained was suspended in 1N NaOH, subjected to
10 ultrasound and filtered to afford 1.95g of pure amide.

 A solution of the amide (1.95g) in tetrahydrofuran (150ml) was stirred at 0°C under a nitrogen atmosphere and was treated with anhydrous triethylamine (6.95ml) followed by a solution of
15 trifluoroacetic anhydride (4.3ml) in tetrahydrofuran. The reaction mixture was stirred for 30 mins then partitioned between water and diethyl ether.

 The organic phase was separated, the solvent was removed
20 in vacuo and the residue was dissolved in 200ml methanol-water (1:1) containing potassium carbonate (15g). The reaction mixture was heated at 70°C for 24hrs, cooled, extracted into ethyl acetate, washed with water (3 x) and brine (1 x), dried (MgSO₄) and the solvent was removed under vacuum to give 5-
25 chloroanthranilonitrile.

- 35 -

o-Methoxyphenyl acetyl chloride (0.8g) and the product from above (0.6g) were heated under reflux in dichloromethane (50ml) for 14h. The solvent was removed in vacuo and the residue was suspended in methanol and filtered to give the amide.

5

A solution of the amide (0.9g) in DMF (50ml) was treated with sodium hydride (1.2g of 80% disp. in oil) and the reaction was heated at 100°C for 1.5h. The cooled reaction mixture was partitioned between ethyl acetate-water, and the organic phase was separated and washed with water (2 x), brine (1 x) and dried (MgSO₄). The solvent was removed and the residue was purified by preparative HPLC to give the title compound (0.1g); mp 284-286°C; Found: C, 60.26; H, 4.35; N, 9.02; C₁₆H₁₃N₂O₂Cl.1.0H₂O requires C, 60.29; H, 4.74; N, 8.79%. δ (360 MHz, DMSO-d₆) 3.70 (3H, s, ArOCH₃), 5.73 (2H, s, NH₂), 6.81-7.69 (6H, m, aromatics), 8.00 (1H, d, J = 8.7Hz, 5-H), 11.01 (1H, s, NHCO). m/z (CI⁺) 301 (M+1).

10
15

EXAMPLE 2

20

4-Amino-7-chloro-3-phenyl-2(1H)-quinolone

5-Chloroanthranilonitrile (an Intermediate in Example 1) (0.9g, 5.9mmol) and phenylacetyl chloride were reacted in a similar manner to that described in Example 1 to give the title compound (0.87g); mp 337-338°C (MeOH, DMF, H₂O). Found:

25

- 36 -

C, 66.10; H, 4.25; N, 10.35. $C_{15}H_{11}ClN_2O$ requires C, 66.55; H, 4.10; N, 10.38%; δ (360 MHz, DMSO- d_6) 5.96 (2H, br s, NH_2), 7.14-8.04 (8H, m, aromatics), 11.10 (1H, br s, NH); m/z (EI) 270 (M^+).

5

EXAMPLE 34-Amino-7-chloro-3-(3-phenoxyphenyl)-2(1H)-quinolone

10

5-Chloro anthranilonitrile (0.9g, 5.9mmol) and 3-phenoxyphenyl acetic acid were reacted in a manner similar to that described in Example 1 to give the title compound (0.31g); mp 196-197°C (dichloromethane); δ (360 MHz, DMSO- d_6) 6.09 (2H, br s, NH_2), 6.70-8.05 (12H, m, aromatics), 11.06 (1H, br s, NH); m/z (CI^-) 362 (M^+).

15

EXAMPLE 47-Chloro-4-methanesulphonamido-3-phenyl-2(1H)-quinolone

20

A solution of 4-amino-7-chloro-3-phenyl-2(1H)-quinolone (0.55g, 2mmol) (Example 2) and potassium (bistrimethylsilyl) amide (4ml, 0.5M solution in toluene) in 50ml tetrahydrofuran were stirred for 10 mins prior to the addition of tert-butyldimethylsilyl trifluoromethanesulfonate (6.1ml). After a further 10 mins a further portion of potassium(bistrimethylsilyl)amide (6.1ml) was added followed after 10 mins by methanesulfonyl chloride (0.48ml). The solvent

25

- 37 -

was removed in vacuo after one hour and the residue was suspended in 5N HCl (30ml), and treated with ultrasound for 5 mins before being filtered. The solid was suspended in 1N NaOH and re-exposed to ultrasound then filtered to give the
5 title compound (0.077g); mp 222-224°C (DMF-water-diethyl ether); δ (360 MHz, DMSO- d_6) 2.17 (3H, s, CH₃), 7.34-7.67 (8H, m, aromatics), 9.60 (1H, br s, NHSO₂), 12.16 (1H, br s, NHCO); m/z (EI) 348 (M⁺).

10

EXAMPLE 57-Chloro-4-phenylsulphonamido-3-phenyl-2(1H)-quinolone

Benzene sulphonylchloride (0.94ml) and 4-amino-7-chloro-3-phenyl-2(1H)-quinolone (1g) (Example 2) were reacted in a
15 similar manner to that as described in Example 4. An additional step was required to remove the tert butyldimethylsilyl protecting group using methanolic-HCl for 20 mins to afford the title compound (0.050g); mp 268°C (ethanol);
20 δ (360 MHz, DMSO- d_6) 7.14 (6H, m, aromatics), 7.32 (5H, m, aromatics), 7.49 (1H, m, aromatics), 7.67 (1H, d, J = 8.7Hz, 5-H), 10.02 (1H, br s, 4NH), 12.15 (1H, br s, 1NH); m/z 410 (M⁺).

SUBSTITUTE SHEET

- 38 -

EXAMPLE 64-Acetamido-7-chloro-3-phenyl-2(1H)-quinolone

5 A solution of 4-amino-7-chloro-3-phenyl-2(1H)-quinolone (Example 2) (0.3g) in tetrahydrofuran (30ml) was treated with sodium hydride (0.2g, 80% disp. in oil). After 1h, acetyl chloride (0.7ml) was added and the reaction mixture was stirred for 2h at room temperature then heated under reflux for 14h. The reaction was partitioned between water and ethyl acetate. The organic phase was dried (MgSO₄) and the solvent was removed in vacuo. The residue was suspended in 1N NaOH, and placed in an ultrasound bath for 5 mins. The aqueous phase was extracted with diethyl ether, acidified to pH1 and the precipitate produced was collected by filtration to give the title compound (0.080g); mp 275-277°C (DMF-water). Found: C, 58.39; H, 4.83; N, 8.02. C₁₇H₁₃ClN₂O₂.2H₂O requires C, 58.54; H, 4.91; N, 8.03%; δ (360 MHz, DMSO-d₆) 1.88 (3H, s, CH₃CO), 7.22-7.58 (8H, m, aromatics), 9.69 (1H, br s, NH), 12.06 (1H, br s, NH); m/z (EI) 312 (M⁺).

EXAMPLE 74-Carboxycarbonylamino-7-chloro-3-phenyl-2(1H)-quinolone

25

4-Amino-7-chloro-3-phenyl-2(1H)-quinolone (Example 2) (0.3g) and ethyl oxalyl chloride (1.1ml) were reacted in a similar

- 39 -

manner to that described in Example 6 to give the title compound; mp 240°C decomposed; Found: C, 57.70; H, 3.46; N, 7.93. $C_{17}H_{11}N_2O_4Cl \cdot 0.5H_2O$ requires C, 58.05; H, 3.44; N, 7.96%. δ (360 MHz, DMSO) 7.25-7.41 (7H, m, aromatics), 7.59 (1H, d, $J = 8.7$ Hz, 5-H), 10.63 (1H, s, $NHCOCO_2H$), 12.20 (1H, s, NH); m/z (Cl^+) 342 ($M+1$).

EXAMPLE 8

10 7-Chloro-4-methoxycarbonylcarbonylamino-3-phenyl-2(1H)-quinolone

The product from Example 7 (0.34g) was treated with saturated methanolic hydrogen chloride at room temperature for 14h. The solvent was removed in vacuo and the residue was azeotroped with toluene (2 x), then purified by chromatography (30 to 100% ethyl acetate-petrol eluent). This was followed by preparative HPLC to give the title compound (0.1g); mp 240°C decomp (methanol-water); Found: C, 57.77; H, 3.78; N, 6.98; $C_{18}H_{13}N_2O_4Cl \cdot 1.1H_2O$ requires C, 57.41; H, 4.07; N, 7.44%. δ (360 MHz, DMSO- d_6) 3.77 (3H, s, CO_2CH_3), 7.25-7.42 (7H, m, aromatics), 7.65 (1H, d, $J = 8.7$ Hz, 6-H), 12.20 (1H, s, NH). m/z (Cl^+) 357 ($M+1$);

25

EXAMPLE 9

4-Carboxymethylcarbonylamino-7-chloro-3-phenyl-2(1H)-quinolone

SUBSTITUTE SHEET

- 40 -

A solution of 4-amino-7-chloro-3-phenyl-2(1H)-quinolone (Example 2) (0.5g) in 50ml tetrahydrofuran was stirred under an atmosphere of nitrogen and treated with sodium hydride (0.3g, 80% disp. in mineral oil). This was followed by the addition after 1h of ethyl malonyl chloride (1.8ml). The reaction mixture was heated at 60°C for 14h, cooled and partitioned between ethyl acetate and water. The organic phase was washed with water (2 x) before the solvent was removed in vacuo. The residue was saponified using 4N sodium hydroxide (100ml) and ultrasound. The solution was adjusted to pH1 using conc. HCl then extracted into ethyl acetate, dried (MgSO₄) and the solvent was removed in vacuo. The residue was purified by preparative HPLC followed by recrystallisation from DMF-water to give the title compound (50mg); mp 260°C decomposed; δ (360 MHz, DMSO) 3.22 (2H, s, CH₂CO₂H), 7.22-7.76 (7H, m, aromatics), 7.87 (1H, d, 5-H, $J = 8.4$ Hz), 9.97 (1H, s, NHCOCH₂CO₂H), 12.13 (1H, s, NH). Found: C, 60.29; H, 3.83; N, 7.69. C₁₈H₁₃N₂O₄Cl requires C, 60.60; H, 3.67; N, 7.85%.

20

EXAMPLE 104-(2-Dimethylaminoethylamino)-7-chloro-3-phenyl-2(1H)-quinolone

25

7-Chloro-4-hydroxy-3-phenyl-2(1H)-quinolone (1g) and N,N-dimethylethylenediamine (30ml) were heated in a sealed tube at 180°C for 10 days. The reaction mixture was concentrated in

SUBSTITUTE SHEET

- 41 -

vacuo and partitioned between ethyl acetate and saturated potassium carbonate solution. The organic layer was separated, dried (Na_2SO_4) and the solvent was removed under vacuum. The residue was dissolved in HCl, washed with diethyl ether (2
5 x), then basified with sodium hydroxide, extracted into ethyl acetate, dried (MgSO_4), and concentrated in vacuo, to give 0.248g of the title compound; mp 230°C (ethyl acetate); Found: C, 63.76; H, 5.64; N, 11.75. $\text{C}_{19}\text{H}_{20}\text{ClN}_3\text{O} \cdot 0.9\text{H}_2\text{O}$ requires C, 63.37; H, 6.14; N, 11.76%. δ (360 MHz, DMSO-d_6) 1.94 (6H, s, $(\text{CH}_3)_2\text{N}$), 2.17 (2H, m, $\text{NCH}_2\text{CH}_2\text{N}$), 2.69 (2H, m, $\text{NCH}_2\text{CH}_2\text{N}$), 5.82 (1H, br s, NH), 7.17-7.95 (8H, m, aromatics),
10 11.23 (1H, br s, NH); m/z (Cl^+) 341 (M^+).

EXAMPLE 11

15

4-(3-Dimethylaminopropylamino)-7-chloro-3-phenyl-2(1H)-quinolone

7-Chloro-4-hydroxy-3-phenyl-2(1H)-quinolone (1g) and 3-
20 dimethylaminopropylamine (30ml) were heated together in a similar manner to that described for Example 10 to give the crude product, which was suspended in a mixture of 1:1 ethyl acetate and 1N HCl and filtered. The aqueous phase was
basified to pH14 with sodium hydroxide and then extracted into
25 ethyl acetate. The organic layer was dried (MgSO_4) and the solvent was removed to give the title compound (0.090g); mp $177-179^\circ\text{C}$ (diethyl ether). Found: C, 67.27; H, 6.22; N, 11.61.

SUBSTITUTE SHEET

- 42 -

C₂₀H₂₂ClN₃O requires C, 67.50; H, 6.23; N, 11.81%; δ (360 MHz, DMSO-d₆) 1.38 (2H, m, NCH₂CH₂CH₂N(CH₃)₂), 1.98 (2H, m, NCH₂CH₂CH₂N(CH₃)₂), 2.04 (6H, s, N(CH₃)₂), 2.58 (2H, m, NCH₂CH₂CH₂N(CH₃)₂), 6.58 (1H, m, NHCH₂CH₂CH₂N), 7.19-7.94 (8H, m, aromatics), 11.15 (1H, br s, NHCO); m/z (CI⁻) 355 (M⁺).

EXAMPLE 12

10 4-Benzylamino-7-chloro-3-phenyl-2(1H)-quinolone

7-Chloro-4-hydroxy-3-phenyl-2(1H)-quinolone (0.5g) and benzylamine (20ml) was heated under reflux for 24h. The reaction was concentrated under high vacuum and the residue was triturated with diethyl ether and filtered. The filtrate was evaporated and purified by chromatography (25% ethyl acetate-dichloromethane eluent) to give the title compound as a white solid (0.045g); mp 179°C (diethyl ether). Found: C, 72.63; H, 4.45; N, 7.65. C₂₂H₁₇ClN₂O.0.1H₂O requires C, 72.87; H, 4.78; N, 7.72%; δ (360 MHz, DMSO-d₆) 3.81 (2H, d, J = 4.8Hz, PhCH₂NH), 8.67 (1H, t, J = 4.8Hz, PhCH₂NH), 6.85 (2H, d, J = 6.5Hz, ortho aromatics), 7.10-7.33 (11H, m, aromatics), 8.16 (1H, d, J = 8.8Hz, 5-H), 11.23 (1H, br s, NH); m/z (EI) 360 (M⁺).

SUBSTITUTE SHEET

- 43 -

EXAMPLE 137-Chloro-4-(prop-2-en)oxy-3-phenyl-2(1H)-quinolone

5 7-Chloro-4-hydroxy-3-phenyl-2(1H)-quinolone (0.24g, 8.8mmol) and allylbromide (0.0765ml) were stirred with sodium hydrogen carbonate (0.743g) in DMF (10ml) for 40h. A further 0.5 equivalents of allyl bromide was added after 18h. Water (100ml) was added to the reaction mixture and the solid
10 produced was collected by filtration. Trituration with methanol gave the title compound (0.090g); mp 192-193°C (methanol). Found: C, 68.73; H, 4.59; N, 4.48. $C_{18}H_{14}ClNO_2 \cdot 0.2H_2O$ requires C, 68.55; H, 4.60; N, 4.44%; δ (360 MHz, DMSO- d_6) 4.06 (2H, d, $J = 5.8$ Hz, $OCH_2CH=CH_2$), 5.12 (2H, m, $OCH_2CH=CH_2$), 5.76 (1H, m, $OCH_2CH=CH_2$), 7.25-7.83 (8H, m, aromatics), 11.90 (1H, br, s, NH); m/z (Cl^-) 311 (M^+).

EXAMPLE 14

20 7-Chloro-4-methoxycarbonylmethoxy-3-phenyl-2(1H)-quinolone

A solution of 7-chloro-4-hydroxy-3-phenyl-2(1H)-quinolone (0.5g) in DMF was stirred for 14h with methyl bromoacetate (206 μ l) and sodium bicarbonate (1.55g). The reaction mixture
25 was then partitioned between water and ethyl acetate. The aqueous phase was extracted with two further portions of ethyl

SUBSTITUTE SHEET

- 44 -

acetate. The combined organic phases were washed with brine (3 x), dried (MgSO_4) and the solvent was removed in vacuo to give the crude product which was recrystallised from ethyl acetate-hexane to give the title compound, 208mg; mp 188-191°C (ethyl acetate-hexanes); Found: C, 63.27; H, 4.24; N, 4.07. $\text{C}_{18}\text{H}_{14}\text{ClNO}_4$ requires C, 62.89; H, 4.11; N, 4.07%; δ (360 MHz, DMSO-d_6) 3.55 (3H, s, CO_2CH_3), 4.19 (2H, s, CH_2CO_2), 7.28 (1H, dd, $J = 2.6, 8.7\text{Hz}$, 6-H), 7.35-7.40 (6H, m, aromatics), 8.01 (1H, d, $J = 8.7\text{Hz}$, 5-H), 11.92 (1H, s, NH); m/z Cl^+ 344 (M^+).

EXAMPLE 15

4-Carboxymethoxy-7-chloro-3-phenyl-2(1H)-quinolone

15

A solution of 4-methoxycarbonylmethoxy-7-chloro-3-phenyl-2(1H)-quinolone (Example 14) (0.13g) in 50ml tetrahydrofuran was stirred at room temperature for 30 mins with lithium hydroxide (18.2ml, 0.5M solution). The solvent was removed in vacuo and the residue was dissolved in water and acidified to pH1 (1N HCl). The precipitate was collected by filtration to give the title compound, 23mg; mp 269-272°C (propan-2-ol then DMF-water); Found: C, 61.63; H, 3.61; N, 4.60. $\text{C}_{17}\text{H}_{12}\text{NO}_4\text{Cl}$ requires C, 61.92; H, 3.69; N, 4.25%. δ (360 MHz, DMSO-d_6) 4.05 (2H, s, OCH_2), 7.29 (1H, dd, $J = 2.7, 8.7\text{Hz}$, 6-H), 7.35-7.47 (6H, m, Ar + 8-H), 8.07 (1H, d, $J = 8.7\text{Hz}$, 5-H), 11.68 (1H, s, N-H). m/z (Cl^-) 328 ($\text{M}-1$);

SUBSTITUTE SHEET

- 45 -

EXAMPLE 164-Methoxycarbonylmethyl-7-chloro-3-phenyl-2(1H)-quinolone

5

A solution of methyl 3-(2-amino-4-chloro)-phenyl prop-2-enoate (4g, 19mmol) and phenacetylchloride (5ml, 38mmol) in dichloromethane (100ml) was heated under reflux for 14h. The solvent was removed in vacuo, and the residue was azeotroped with methanol (100ml). Trituration with methanol gave an intermediate amide; δ (360 MHz, DMSO- d_6) 3.73 (3H, s, CO₂CH₃), 6.60 (1H, d, J = 15.9Hz, CH_A=CH_B CO₂CH₃), 7.24-7.38 (6H, m, aromatics + H-4), 7.55 (1H, d, J = 2.1Hz, H-6), 7.76 (1H, d, J = 15.9Hz, CH_A=CH_BCO₂CH₃), 7.85 (1H, d, J = 8.6Hz, H-3).

15

A solution of this amide (0.5g, 1.5mmol) in anhydrous tetrahydrofuran was cooled to -78°C under a nitrogen atmosphere, and was treated with potassium bis(trimethylsilyl)amide (3.64ml, 0.5M solution) via dropwise addition. After 10 mins t-butyldimethylsilyl trifluoromethanesulfonate (0.418ml) was added and the reaction mixture was stirred for a further 45 mins prior to the addition of a further 1.2 equivalents of potassium bis(trimethylsilyl) amide.

25 A solution of phenyl selenylchloride (0.316g) in tetrahydrofuran (10ml) was added after 10 mins. The reaction mixture was allowed to stir at -78°C for 30 mins and then at room temperature for 14h.

SUBSTITUTE SHEET

- 46 -

The reaction mixture was partitioned between ethyl acetate and saturated aqueous ammonium chloride. The aqueous phase was extracted with two further portions of ethyl acetate. The combined organic phases were washed with saturated aqueous brine, dried (MgSO_4) and all the solvent was removed in vacuo. The residue was purified by chromatography (15% ethyl acetate-hexane as eluent). The purified selenide was dissolved in 20ml methanol-water (7:1) and was treated with sodium periodate (245mg) for one hour. The precipitate was collected by filtration and purified by chromatography (30-50% ethyl acetate-hexane eluent) and preparative HPLC (40% acetonitrile-water eluent) to give the title compound (0.021g); mp 227°C ; Found: C, 63.95; H, 4.34; N, 4.13. $\text{C}_{18}\text{H}_{14}\text{ClNO}_3 + 0.5\text{H}_2\text{O}$ requires C, 64.19; H, 4.49; N, 4.16%. δ (360 MHz, DMSO-d_6) 3.58 (3H, s, methyl ester), 3.75 (2H, s, $\text{CH}_2\text{CO}_2\text{CH}_3$), 7.18 (2H, m, H-8 + aromatics), 7.26 (1H, dd, $J = 2.1$ and 8.7Hz , H-6), 7.42 (4H, m, aromatics), 7.69 (1H, d, $J = 8.7\text{Hz}$, H-5), 12.07 (1H, s, NH); m/z (EI^+) 327 (M^+).

20

EXAMPLE 174-Carboxymethyl-7-chloro-3-phenyl-2(1H)-quinolone

A suspension of methoxycarbonylmethyl-7-chloro-3-phenyl-2(1H)-quinolone (0.12g) (Example 16) in 50% methanol-water (20ml) was heated under reflux for one hour with sodium hydroxide (200mg). The methanol was removed under vacuum,

25

SUBSTITUTE SHEET

- 47 -

and the residue was extracted with three portions of diethyl ether. The aqueous phase was acidified (c.HCl) and extracted with three portions of ethyl acetate. The combined organic extracts were washed with brine, dried (MgSO₄) and the solvent was removed in vacuo, to give the title compound (0.05g); mp 175°C (ethanol); Found: C, 64.80; H, 4.23; N, 4.42. C₁₇H₁₂ClNO₃ requires C, 65.08; H, 3.86; N, 4.46%. δ (360 MHz, DMSO-d₆) 5.65 (2H, s, -CH₂CO₂H), 7.23 (2H, aromatics), 7.26 (1H, dd, J = 2.1, 8.6Hz, H-6), 7.41 (4H, m, aromatics), 7.69 (1H, d, J = 8.6Hz, H-5), 12.03 (1H, s, NH), 12.68 (1H, br s, CO₂H); m/z (CI⁺) 313 (M⁺).

EXAMPLE 18

4-Carboxy-7-chloro-3-phenyl-2(1H)-quinolone

A mixture of 4- and 6-chloroisatin (2.72g), phenyl acetic acid (3.57g) and sodium acetate (0.3g) were heated at 220°C for 1h. Acetic acid (20ml) was added to the hot reaction mixture, and the cooled solution was partitioned between saturated sodium carbonate and ethyl acetate. The aqueous phase was acidified to pH1 (c.HCl), and the precipitate was collected by filtration to give the title compound (60mg); mp 258°C (ethanol); (Found: C, 63.94; H, 3.32; N, 4.59. C₁₆H₁₀ClN₁O₃ requires C, 64.12; H, 3.36; N, 4.67%); δ (360 MHz, DMSO-d₆) 7.30 (1H, dd, J = 8.7, 2.1Hz, H-6), 7.39 (6H, m, aromatics, H-8), 7.50 (1H, d, J = 8.7Hz, H-5), 12.2 (1H, s, NH), 14.0 (1H, br s, CO₂H); m/z = 299 (M⁺).

SUBSTITUTE SHEET

- 48 -

EXAMPLE 197-Chloro-3-(2-aminophenyl)-2(1H)-quinolone

5 A solution of oxalyl chloride (20ml) in CH_2Cl_2 (300ml) was added over 1h to a solution of 2-nitrophenylacetic acid (27g) in DMF (0.5l). 2-Amino-4-chlorobenzylalcohol (9.4g) in CH_2Cl_2 (200ml) was added and the reaction mixture was heated under reflux for 1h. The cooled solution was washed with saturated
10 sodium hydrogen carbonate, brine, dried (MgSO_4) and the solvent was removed in vacuo to leave a black solid which was recrystallised from ethyl acetate-hexane to leave 20.1g of a brown solid.

15 This product was stirred with potassium carbonate (3g) in methanol (300ml) at room temperature for 14h. The solvent was removed in vacuo and the residue was partitioned between water and ethyl acetate. The organic phase was washed with water, brine, dried (MgSO_4) and the solvent was removed in
20 vacuo. The residue was recrystallised to give 7.8g of the amide, mp 155-157°C (propan-2-ol).

The amide was dissolved in CH_2Cl_2 (100ml) and stirred for 2h with pyridinium chlorochromate (4g), ethyl acetate was
25 added, and the reaction mixture was filtered through silica. The solvent was removed and the residue was recrystallised from ethyl acetate to give 1.83g of the aldehyde as white cubes.

SUBSTITUTE SHEET

- 49 -

The aldehyde was stirred with sodium methoxide (0.6g) in methanol (100ml) for 3h. The reaction mixture was concentrated to a volume of 20ml. Trifluoroacetic acid was added and the solid was collected, washed with methanol, and dried to leave 1.48g yellow solid.

The aromatic nitro compound (100mg) was hydrogenated over PtO_2 (20mg) at 50 psi in ethyl acetate (20ml) for 90 mins. The reaction mixture was filtered and the solid was dissolved in hot methanol, the combined filtrates evaporated, and recrystallised to give the title compound as fine yellow needles. mp 287-290°C (methanol); (Found: C, 64.22; H, 4.49; N, 9.85. $\text{C}_{15}\text{H}_{11}\text{N}_2\text{OCl} + 0.5\text{H}_2\text{O}$ requires C, 64.41; H, 4.32; N, 10.01%); δ (360 MHz, DMSO-d_6) 4.34 (2H, s, NH_2), 6.62 (1H, t, $J = 7.2\text{Hz}$, H-5'), 6.73 (1H, d, $J = 7.2\text{Hz}$, H-3'), 7.04 (1H, d, $J = 7.2\text{Hz}$, H-6'), 7.08 (1H, d, $J = 7.2\text{Hz}$, H-4'), 7.24 (1H, dd, $J = 2.1$ and 8.4Hz , H-6), 7.57 (1H, d, $J = 2.1\text{Hz}$, H-8), 7.74 (1H, d, $J = 8.4\text{Hz}$, H-5), 7.92 (1H, s, H-4), 12.0 (1H, s, NH); m/z (Cl^+ , NH_3) 271 ($\text{M}^+ + \text{H}$).

20

EXAMPLE 207-Chloro-3-(4-hydroxyphenyl)-2(1H)-quinolone

2-Amino-4-chlorobenzyl alcohol (4g, 25.3mmol) and 4-methoxyphenyl acetic acid (14.0g, 76.4mmol) were reacted in a similar manner to that described in Example 19 to give 7-chloro-

SUBSTITUTE SHEET

- 50 -

3-(4-methoxyphenyl)-2(1H)-quinolone; mp 256-257°C (ethyl acetate).

5 A suspension of the above product (200mg, 0.7mmol) in CH₂Cl₂ (40ml) was treated with boron tribromide (0.7g, 2.8mmol) at room temperature. A further equivalent of BBr₃ was added after 2h and reaction was complete after 5h. The reaction was washed with saturated sodium hydrogen carbonate, brine and the solvent was evaporated to give the title
10 compound as white needles, mp 262°C (from EtOAc); (Found: C, 65.57; H, 3.97; N, 5.11. C₁₅H₁₀NO₂Cl + 0.15H₂O requires: C, 66.31; H, 3.71; N, 5.15%); δ_{H} (360 MHz, DMSO-d₆) 6.83 (2H, d, J = 6.6Hz, 3'-H), 7.21 (1H, dd, J = 8.4, 2.0Hz, 6-H), 7.53 (1H, d, J = 2.0Hz, 8-H), 7.63 (2H, d, J = 6.6Hz, 2'-H), 7.73 (1H, d, J = 8.4Hz, 5-H), 8.02 (1H, s, 4-H), 9.61 (1H, s, OH), 11.92 (1H, s, NH); m/z (EI⁺) 271 (M⁺).

EXAMPLES 21 & 22

20 7-Chloro-3-(2-methoxyphenyl)-2(1H)-quinolone and 7-Chloro-3-(2-hydroxyphenyl)-2(1H)-quinolone

25 2-Amino-4-chlorobenzyl alcohol (2g, 12.86mmol) and 2-methoxyphenylacetic acid (4.70g, 28.3mol) were reacted in a similar manner as described in Example 19 to give 7-chloro-3-(2-methoxyphenyl)-2(1H)-quinolone as fine white needles mp 235-236°C (MeOH). (Found: C, 67.49; H, 4.22; N, 4.93.

- 51 -

$C_{16}H_{12}ClNO_2$ requires C, 67.26; H, 4.23; N, 4.90%); δ_H (360 MHz, d_6 -DMSO) 3.73 (1H, s, CH_3) 6.97 (1H, dt, $J = 0.8$ and 7.4Hz, 5'-H) 7.08 (1H, d, $J = 8.3$ Hz, 3'-H) 7.22 (1H, dd, $J = 8.4$ and 2.1Hz, 6-H) 2.27 (1H, dd, $J = 7.5$ and 1.7Hz, 6'-H) 7.34 (1H, d, $J = 1.8$ Hz, 8-H) 7.37 (1H, dt, $J = 1.7$ and 8.2Hz, 4'-H) 7.70 (1H, d, $J = 8.4$ Hz, 5-H) 7.87 (1H, s, 4-H) 11.87 (1H, br s, NH); m/z (EI^+) 285 (M^+). The quinolone (300mg) and boron tribromide (3.15ml, 1N solution in CH_2Cl_2) were reacted as described in Example 20 to give 286mg of 7-chloro-3-(2-hydroxyphenyl)-2(1H)-quinolone as a yellow crystalline solid; mp 246-248°C (dec) (methanol). (Found: C, 66.43; H, 3.70; N, 5.17. $C_{15}H_{10}ClNO_2$ requires C, 66.31; H, 3.71; N, 5.15%); δ_H (360 MHz, DMSO- d_6) 6.87 (1H, t, $J = 8.2$ Hz, 5'-H), 6.90 (1H, d, $J = 7.8$ Hz, 3'-H), 7.22 (1H, dt, $J = 1.7$ and 7.8Hz, 4'-H), 7.26 (1H, dd, $J = 8.4$ and 2.1Hz, 6-H), 7.31 (1H, dd, $J = 8.2$ and 1.7Hz, 6'-H), 7.39 (1H, d, $J = 2.1$ Hz, 8-H), 7.77 (1H, d, $J = 8.4$ Hz, 5-H), 8.03 (1H, s, 4-H), 9.56 (1H, br s, OH), 12.14 (1H, br s, NH); m/z (EI^+) 271 (M^+).

20

EXAMPLE 237-Chloro-3-(3-carboxyphenyl)-2(1H)-quinolone

A solution of methyl-3-hydroxyphenylacetate (3.32g, 20mmol) and Hünig's base (4.36ml) in 100ml dichloromethane at 0°C was treated slowly with trifluoromethanesulphonic

SUBSTITUTE SHEET

- 52 -

anhydride. The reaction was stirred for 0.5h at 0°C then 1.5h at room temperature. The reaction was washed with water (50ml), 10% citric acid (50ml), sodium hydrogen carbonate (50ml), dried (MgSO₄), treated with silica and solvent removed in vacuo to leave 5.92g of the triflate as a pale yellow oil. δ (CDCl₃) 3.67 (2H, s, CH₂), 3.72 (3H, s, OMe), 7.18-7.23 (2H, m, 2-H and 4-H), 7.31 (1H, d, J = 8.9Hz, 6-H) and 7.39-7.43 (1H, m, 5-H).

The triflate (1.49g) was mixed with triethylamine (1.4ml), methanol (5ml), DMF (10ml), palladium acetate (40mg) and 1,1'-bis(diphenylphosphine)ferrocene (221mg) to give a brown solution. The reaction was purged with carbon monoxide for 5 mins and then heated to 60°C under an atmosphere of carbon monoxide. Volatiles were removed in vacuo and the residue partitioned between brine and ethyl acetate. The organic extracts were washed with brine, 1N HCl, brine, dried (MgSO₄) and solvent removed in vacuo. The residue was chromatographed (15% to 25% ethyl acetate-petrol) to give the dimethyl ester of 3-(carboxy)phenyl acetic acid as an oil (0.87g). δ (CDCl₃) 3.68 (2H, s, CH₂), 3.70 (3H, s, CH₂CO₂Me), 3.92 (3H, s, ArCO₂Me), 7.39-7.43 (1H, m, 5-H), 7.49 (1H, d, J = 7.7Hz, 6-H) and 7.94-7.96 (2H, m, 2-H and 4-H).

Dimethyl-3-carboxyphenyl acetic acid (870mg) in 10ml tetrahydrofuran was treated with lithium hydroxide (8.5ml, 0.5M solution) at 0°C. After stirring at room temperature for

SUBSTITUTE SHEET

- 53 -

4h, all solvent was evaporated, and the residue partitioned between saturated sodium hydrogen carbonate and ethyl acetate. The aqueous layer was separated, acidified (1N HCl) and extracted with dichloromethane (2 x 25ml). The combined
5 organic layers were dried (MgSO_4) and solvent removed to leave 3-(carboxymethyl)phenyl acetic acid, mp 96-98°C.

To a solution of 4-chloro-2-nitrobenzyl alcohol (15g, 100mmol) in dry DMF (80ml) was added imidazole (14.3g) and
10 tert-butyldimethylsilylchloride (16.6g). The reaction was stirred for 14h and partitioned between diethyl ether and water. The organic phase was dried (MgSO_4) and solvent removed to give the tert-butyldimethylsilyl protected alcohol. δ (250 MHz, CDCl_3) 0.0 (6H, s), 0.8 (9H, s), 4.95 (2H, s), 7.5 (1H, dd, $J = 4$
15 and 8Hz), 7.7 (1H, d, $J = 8\text{Hz}$), 7.77 (1H, d, $J = 4\text{Hz}$).

A solution of the protected alcohol (24g) in ethyl acetate (400ml) was hydrogenated over PtO_2 (2g) at 50 psi over 3h. The reaction was filtered, and solvent removed. The residue was
20 purified by chromatography (10% ethyl acetate-petrol eluent) to give the t-butyldimethylsilyl protected 4-chloro-2-amino benzyl alcohol. δ (360 MHz, CDCl_3) 0.07 (6H, s), 0.91 (9H, s), 4.59 (2H, s), 6.6 (d, $J = 8\text{Hz}$), 6.94 (1H, d, $J = 8\text{Hz}$), 7.28 (1H, s).

25 Oxalyl chloride (1.40ml) was added to a solution of 3-

SUBSTITUTE SHEET

- 54 -

(carboxymethyl)-phenyl acetic acid (2.04g) (from 3 above) in CH_2Cl_2 (30ml) containing DMF (3 drops). The reaction was stirred for 2h, evaporated and azeotroped with CCl_4 (2 x 20ml). The residue was dissolved in CH_2Cl_2 (15ml) and was added to a solution of the amine (3.26g) (from 5 above) in pyridine (10ml) and CH_2Cl_2 (75ml) at 0°C . The reaction was stirred for 14h, evaporated and then partitioned between ethyl acetate and water. The organic phase was separated and washed with 10% citric acid, brine, dried (MgSO_4) and evaporated. The residue was purified by chromatography (10-20% ethyl acetate-petrol eluent) to give the amide. δ (CDCl_3) -0.03 (3H, s, SiMe), -0.01 (3H, s, SiMe), 0.83 (9H, s, t-Bu), 3.71 (2H, s, $-\text{CH}_2\text{CO}-$), 3.89 (3H, s, OMe), 4.57 (2H, s, $-\text{CH}_2\text{O}-$), 6.96 (2H, s, ArH), 7.42 (1H, t, $J = 7.6\text{Hz}$, 5'-H), 7.52-7.55 (1H, m, ArH), 7.95-7.99 (2H, m, ArH), 8.25 (1H, s, ArH) and 8.86 (1H, br s, NH).

HF-pyridine (2ml) was added to a solution of the amide (3.09g) (from 6 above) in dichloromethane (25ml) and pyridine (10ml). The reaction was stirred for 2h with a further 1ml of HF-pyridine being added after 1.5h. Solvent was removed in vacuo, the residue dissolved in ethyl acetate and washed with 1N HCl (3 x), brine, dried (MgSO_4), treated with SiO_2 and evaporated. The benzyl alcohol was recrystallised from ethyl acetate-petroleum ether; δ (CDCl_3) 3.79 (2H, s, $-\text{CH}_2\text{CO}$), 3.93 (3H, s, OMe), 4.49 (2H, s, $-\text{CH}_2\text{OH}$), 6.98-7.03 (2H, m, ArH), 7.46 (1H, t, $J = 7.7\text{Hz}$, ArH), 7.55 (1H, d, $J = 7.6\text{Hz}$, ArH), 7.79 (1H, d, $J = 7.6\text{Hz}$, ArH), 8.04 (1H, s, ArH), 8.19 (1H, s, ArH) and 8.72

SUBSTITUTE SHEET

- 55 -

(1H, br s, NH).

The benzyl alcohol (1.65g) was oxidised and cyclised in a similar manner as described in Example 19 to give the ester
5 (1.2g); mp 263-265°C (DMF-water).

The ester (280mg) was saponified using methanol (15ml) and sodium hydroxide (3ml, 1N solution) at room temperature for 15 mins followed by heating to reflux for 0.5h.
10 Tetrahydrofuran (5ml) was added and reflux continued for 2h. Solvent was removed in vacuo and the residue was suspended in water, and adjusted to pH1 (1N HCl). The precipitate was collected, washed with water then methanol and dried to give the title compound; mp > 330°C (DMF-water). Found: C, 60.95;
15 H, 3.92; N, 4.62. $C_{16}H_{10}ClNO_3 + 0.9H_2O$ requires C, 60.83; H, 3.76; N, 4.43. δ (360 MHz, DMSO- d_6) 7.26 (1H, dd, $J = 8.4$, 2.0Hz, 6-H), 7.37 (1H, d, $J = 2.0$ Hz, 8-H), 7.57 (1H, t, $J = 7.8$ Hz, 5'-H), 7.80 (1H, d, $J = 8.4$ Hz, 5-H), 7.95-8.01 (2H, m, 4'-H and 6'-H), 8.23 (1H, s, 4-H), 8.35 (1H, s, 2'-H) and 12.09 (1H, br s, NH).

20

EXAMPLE 24

7-Chloro-3-phenyl-4-[(2-oxo)propoxy]-2(1H)-quinolone

25

To a stirred suspension of 7-chloro-4-hydroxy-3-phenyl-2(1H)-quinolone (0.50g 0.0018mol), sodium hydrogen carbonate

SUBSTITUTE SHEET

- 56 -

(1.55g, 0.018mol) and sodium iodide (0.20g) in N,N-dimethylformamide (20ml) was added chloroacetone (0.20g, 0.0020mol). The reaction was stirred for 24h, then the product was precipitated by the addition of water (50ml). The product
5 was collected by filtration, washed with water (3 x 10ml) and dried under vacuum at 60°C. Recrystallisation from ethyl acetate/60-80 petrol gave a white crystalline solid; yield = 390mg, mp = 185-186°C; Found: C, 66.20; H, 4.33; N, 4.20; $C_{18}H_{14}ClNO_3$ requires C, 65.96; H, 4.31; N, 4.27. δ (360 MHz, DMSO- d_6), 1.84 (3H, s, CH_3CO), 4.26 (2H, s, CH_2), 7.26 (1H, dd,
10 $J = 8.7$ and 2.1Hz, 6-H), 7.30-7.46 (6H, m, aromatics), 8.02 (1H, d, $J = 8.7$ Hz, 5-H), 11.90 (1H, s, br, NH). MS (CI) $m/z = 328$ (MH) $^+$.

15

EXAMPLE 257-Chloro-3-phenyl-4-[(2-oximino)propoxy]-2(1H)-quinolone

The product from Example 24 (0.50g, 0.0015mol),
20 hydroxylamine hydrochloride (0.21g, 0.0031mol) and 4A molecular sieves were suspended in pyridine (10ml) and heated at 60°C for 14h. A further amount of hydroxylamine hydrochloride (0.42g, 0.0062mol) was added and the reaction mixture heated under reflux for a further 24h. The reaction
25 mixture was diluted with ethyl acetate (30ml) and filtered through hiflo. The mixture was washed with 1N hydrochloric acid (100ml), the acid layer was back extracted with ethyl acetate (2 x 20ml) and the combined organic layers were washed

SUBSTITUTE SHEET

- 57 -

consecutively with water (20ml), saturated sodium hydrogen carbonate solution (20ml) and brine (20ml), then dried (MgSO_4), filtered, and concentrated in vacuo to give a white solid. This was recrystallised from ethanol/water to give a white crystalline solid; yield = 278mg. Mp = 196-198°C. Found: C, 62.93; H, 4.37; N, 8.10. $\text{C}_{18}\text{H}_{15}\text{ClN}_2\text{O}_3$ requires C, 63.07; H, 4.41; N, 8.17. δ (360 MHz, DMSO-d_6), 1.60 (3H, s, CH_3), 4.06 (2H, s, OCH_2), 7.28 (1H, dd, $J = 8.6$ and 2.1Hz , 6-H), 7.32-7.48 (6H, m, aromatics), 7.78 (1H, d, $J = 8.7\text{Hz}$, 5-H), 10.88 (1H, s, NOH), 11.92 (1H, s, br, NH). MS (CI) $m/z = 343$ $[\text{MH}]^+$.

EXAMPLE 26

7-Chloro-3-phenyl-4-(prop-2-ynyloxy)-2(1H)-quinolone

15

This was prepared as for Example 24 but using propargyl bromide (0.48g, 0.0044mol) and 7-chloro-4-hydroxy-3-phenyl-2(1H)-quinolone (0.50g, 0.0018mol) and recrystallising the product from ethanol/water; yield = 210mg as a white crystalline solid, mp = 183-185°C. Found: C, 69.21; H, 3.68; N, 4.34. $\text{C}_{18}\text{H}_{12}\text{ClNO}_2 + 0.1 \text{H}_2\text{O}$ requires C, 69.39; H, 3.95; N, 4.50. δ (360 MHz, DMSO-d_6), 3.50 (1H, t, $J = 2.3\text{Hz}$, CCH), 4.26 (2H, d, $J = 2.5\text{Hz}$, OCH_2C), 7.28 (1H, dd, $J = 8.5$ and 1.9Hz , H_6), 7.32-7.48 (6H, m, aromatics), 7.86 (1H, d, $J = 8.6\text{Hz}$, H_5), 11.96 (1H, s, br, NH). MS (CI) $m/z = 310$ $[\text{MH}]^+$.

25

- 58 -

EXAMPLE 277-Chloro-3-phenyl-4-[2-(O-methyl)oximino]propyloxy-2(1H)-quinolinone

5

The product from Example 24 (0.50g, 0.0015mol), O-methylhydroxylamine hydrochloride (0.25g, 0.0031mol) and 4A molecular sieves were suspended in pyridine (10ml) and heated at 60°C for 14h. The reaction mixture was cooled, the solvent was removed in vacuo and the resulting solid was redissolved in ethyl acetate (200ml). The solution was washed with 1N hydrochloric acid (50ml), the acid layer was back extracted with ethyl acetate (2 x 25ml) and the combined organic layers were washed consecutively with water (20ml), saturated sodium carbonate solution (20ml), and brine (20ml) and then dried (MgSO₄), filtered, and the solvents removed in vacuo to give a white solid. This was recrystallised from ethanol/water to give the desired product as white needles; yield = 185mg. Mp = 192-195°C. Found: C, 63.52; H, 4.83; N, 7.66. C₁₉H₁₇ClN₂O₃ · 0.1 H₂O requires C, 63.63; H, 4.83; N, 7.81. δ (360 MHz, DMSO-d₆) 1.58 (3H, s, CCH₃), 3.71 (3H, s, NOCH₃), 4.06 (2H, s, OCH₂), 7.28 (1H, dd, J = 8.7 and 2.1Hz, 6-H), 7.32-7.48 (6H, m aromatics), 7.80 (1H, d, J = 8.6Hz, 5-H), 11.91 (1H, s, br, NH). MS (CI) m/z = 355 [MH]⁺.

25

SUBSTITUTE SHEET

- 59 -

EXAMPLE 287-Chloro-4-methoxycarbonylmethoxy-3-(3-phenoxy)phenyl-
2(1H)-quinolone

5

To a solution of 7-chloro-4-hydroxy-3-(3-phenoxy)phenyl-
-2(1H)-quinolone (1.5g) in DMF (50ml) under nitrogen at room
temperature, was added NaHCO_3 (3.5g) followed by methyl
bromoacetate (0.57ml). The reaction mixture was stirred at
10 room temperature for 16h, then poured into water (110ml) and
extracted with ethyl acetate (2 x 100ml). The combined organic
layers were washed with brine (2 x 75ml), dried (MgSO_4),
filtered and the solvent was removed in vacuo to leave a solid
residue. Recrystallisation from an ethyl acetate, petrol (60-80)
15 mixture and then recrystallisation from dichloromethane, petrol
(60-80) mix gave the title compound (0.36g); mp 190-192°C.
Found: C, 65.93; H, 4.33; N, 3.31; $\text{C}_{24}\text{H}_{18}\text{NO}_5\text{Cl}$ requires C,
66.14; H, 4.16; N, 3.21%. δ (360 MHz, DMSO-d_6) 3.59 (3H, s,
 $\text{OCH}_2\text{CO}_2\text{CH}_3$), 4.30 (2H, s, $\text{OCH}_2\text{CO}_2\text{CH}_3$), 7.03-7.48 (11H, m,
20 Ph + Ph + 6-H + 8-H), 7.99 (1H, d, $J = 8.65\text{Hz}$, 5-H), 11.91 (1H,
bs, NH). m/z (Cl^+), 436, (M+1).

EXAMPLE 29

25

4-Carboxymethoxy-7-chloro-3-(3-phenoxy)phenyl-2(1H)-
quinolone

To a solution of 7-chloro-4-methoxycarbonylmethoxy-3-(3-

- 60 -

phenoxy)-2(1H)-quinolone (Example 28, 0.24g) in tetrahydrofuran (50ml) at room temperature, was added a 0.5N solution of lithium hydroxide (26.45ml). The reaction mixture was stirred at room temperature for 1h, then the organic solvent was removed in vacuo. The aqueous residue was acidified to pH 1 using concentrated HCl and the emerging precipitate was collected by filtration and dried at 50°C for 2h to give the title compound (0.05g). Mp 246-249°C. Found: C, 62.61; H, 3.72; N, 3.30; $C_{23}H_{16}NO_5Cl \cdot H_2O$ requires C, 62.80; H, 4.12; N, 3.19%. δ (360 MHz, DMSO- d_6) 4.18 (2H, s, OCH_2CO_2H), 7.04-7.48 (11H, m, Ph + Ph + 6-H + 8-H), 8.02 (1H, d, $J = 8.55$ Hz, 5-H), 11.93 (1H, bs, NH). m/z (FAB⁺), 422, (m+1).

EXAMPLE 30

15

7-Chloro-4-cyanomethoxy-3-phenyl-2(1H)-quinolone

20

To a solution of 7-chloro-4-hydroxy-3-phenyl-2(1H)-quinolone (0.50g, 1.84mmol) in dimethyl formamide (50ml) under nitrogen at room temperature, was added sodium hydrogen carbonate (1.50g) followed by bromoacetonitrile (1.9ml). The reaction mixture was stirred at room temperature for 16h, then poured into water and extracted with ethyl acetate (3 x 50ml). The combined organic layers were washed with water (2 x 50ml), dried ($MgSO_4$), filtered and the solvent was removed in vacuo to leave an oily residue. Trituration with diethyl ether, followed by recrystallisation from an ethyl

25

SUBSTITUTE SHEET

- 61 -

acetate, petrol (60-80) mixture, gave the title compound as a white solid (0.15g). Mp 209-211°C. Found: C, 65.60; H, 3.74; N, 8.75; $C_{17}H_{11}N_2O_2Cl$ requires C, 65.71; H, 3.57; N, 9.02%. δ (360 MHz, DMSO- d_6) 4.59 (2H, s, OCH_2CN), 7.31 (1H, dd, $J = 8.63$ Hz, $J = 2.10$ Hz, 6-H), 7.40-7.49 (6H, m, Ph + 8-H), 7.83 (1H, d, $J = 88.63$ Hz, 5-H), 12.10 (1H, bs, NH). m/z (Cl^+), 311, (M+1).

EXAMPLE 31

10 7-Chloro-4-cyanomethoxy-3-(3-phenoxy)phenyl-2(1H)-quinolone

To a solution of 7-chloro-4-hydroxy-3-(3-phenoxy)phenyl-2(1H)-quinolone (0.75g, 2.06mmol) in dimethyl formamide (50ml) under nitrogen at room temperature, was added sodium hydrogen carbonate (1.80g) followed by bromoacetonitrile (0.21ml). The reaction mixture was stirred at room temperature for 16h, then poured into water (100ml) and the emerging precipitate was filtered. Recrystallisation from an EtOAc, petrol (60-80) mixture gave the title compound in 16% yield (0.13g). Mp 218-220°C. Found: C, 68.97; H, 3.67; N, 6.88; $C_{23}H_{15}N_2O_3Cl$ requires C, 68.58; H, 3.75; N, 6.95%. δ (360 MHz, DMSO- d_6) 4.70 (2H, s, OCH_2CN), 7.08-7.51 (11H, m, Ph + Ph + 6-H + 8-H), 7.82 (1H, d, $J = 8.67$ Hz, 5-H), 12.10 (1H, bs, NH). m/z (Cl^+), 403, (M+1).

SUBSTITUTE SHEET

- 62 -

EXAMPLE 327-Chloro-4-N,N-dimethylaminocarbonylmethoxy-3-phenyl-
2(1H)quinolone

5

To a saturated solution of dimethylamine in methanol (200ml) at 0°C was added 7-chloro-4-methoxycarbonyl methoxy-3-phenyl-2(1H)-quinolone (Example 28, 0.30g). The reaction mixture was sealed and left for 5 days. Removal of the solvent
10 in vacuo and recrystallisation from an EtOAc, MeOH mixture gave the title compound (0.21g). Mp 232-234°C. Found: C, 64.38; H, 4.92; N, 7.78; C₁₉H₁₇N₂O₃Cl requires C, 63.96; H, 4.80; N, 7.85%. δ (360 MHz, DMSO-d₆) 2.42 (3H, s, OCH₂NCH₃), 2.69 (3H, s, OCH₂NCH₃), 4.30 (2H, s, OCH₂N(CH₃)₂), 7.24 (1H, dd, J = 8.62Hz, J = 2.05Hz, 6-H),
15 7.32-7.47 (6H, m, Ph + 8-H), 7.98 (1H, d, J = 8.62Hz, 5-H), 11.83 (1H, s, NH). m/z (CI⁺), 403, (m+1).

EXAMPLE 33

20

7-Chloro-4-(2-N,N dimethylaminoethyl)oxy-3-phenyl-
2(1H)quinoloneA. 4-(Prop-2-enyloxy)-7-chloro-3-phenyl-2(1H)-quinolone

25

To a solution of 7-chloro-4-hydroxy-3-phenyl-2(1H)-quinolone (5.00g) in dimethyl formamide (150ml) under nitrogen at room temperature, was added sodium hydrogen carbonate

SUBSTITUTE SHEET

- 63 -

(15.47g). The reaction mixture was stirred at room temperature for 30 mins then allyl bromide (2.39ml) was added, and stirring continued for a further 36h at room temperature. The mixture was poured into water (200ml) and the emerging precipitate was filtered and triturated with boiling methanol to give the desired compound as a beige solid in 50% yield. ¹H NMR (360 MHz, DMSO-d₆) δ 4.04 (2H, dd, \underline{J} = 6.45Hz, \underline{J} = 1.84Hz, OCH₂CHCH₂), 5.08 (2H, m, OCH₂CHCH₂), 5.88 (1H, m, OCH₂CHCH₂), 7.23 (1H, dd, \underline{J} = 12.45Hz, \underline{J} = 3.00Hz, 6-H), 7.36 (6H, m, Ph + 8-H), 7.81 (1H, d, \underline{J} = 12.45Hz, 5-H), 11.94 (1H, bs, NH).

B. 7-Chloro-4-(2-N,N dimethylaminoethyl)oxy-3-phenyl-2(1H)-quinolone

15

A solution of 4-(prop-2-enyloxy)-7-chloro-3-phenyl-2(1H)-quinolone (0.30g) in dichloromethane (50ml) at -78°C had ozone passed through for 15 mins (solution turned to an electric blue colour). The reaction mixture was allowed to warm to room temperature and stirred for 1h before adding dimethyl sulfide (0.50ml). After stirring for a further 30 mins the solvent was removed under vacuum to leave a solid residue. The residue was dissolved in methanol (50ml) and dimethylamine hydrochloride (0.40g) and sodium cyanoborohydride (0.06g) were added. The pH of the solution was measured and observed to be 4. The reaction was stirred at room temperature for 16h, then the mixture was basified to pH 9 using 1N sodium hydroxide and the solution was extracted with ethyl acetate (3 x 50ml).

SUBSTITUTE SHEET

- 64 -

The combined organic layers were extracted with 1N HCl (1 x 100ml) and the aqueous layer washed with ethyl acetate (2 x 50ml), before being basified to pH 9 using 1N sodium hydroxide and re-extracted with EtOAc (3 x 50ml). The combined organic
5 layers were dried (MgSO_4), filtered and the solvent was removed in vacuo to leave a solid residue. Recrystallisation from ethyl acetate, then an ethyl acetate petrol (60-80) mix, gave the title compound in a 10% yield (0.03g). Mp 185-187°C. Found: C, 66.31; H, 5.95; N, 7.46; $\text{C}_{19}\text{H}_{19}\text{N}_2\text{O}_2\text{Cl} \cdot 0.1\text{C}_6\text{H}_{14}$
10 $0.6\text{H}_2\text{O}$ requires C, 65.97; H, 5.93; N, 7.85%. δ (360 MHz, DMSO- d_6) 2.00 (6H, s, 2 x NCH_3), 2.33 (2H, t, $J = 5.78\text{Hz}$, $\text{OCH}_2\text{CH}_2\text{N}(\text{CH}_3)_2$), 3.55 (2H, t, $J = 5.78\text{Hz}$, $\text{OCH}_2\text{CH}_2\text{N}(\text{CH}_3)_2$), 7.24 (1H, dd, $J = 9.31\text{Hz}$, $J = 2.10\text{Hz}$, 6-H), 7.35-7.46 (6H, m, Ph + 8-H), 7.91 (1H, d, $J = 9.31\text{Hz}$, 5-H), 11.67
15 (1H, bs, NH). m/z (Cl^+), 343, (m+1).

EXAMPLE 34

4-Aminocarbonylmethoxy-7-chloro-3-phenyl-2(1H)-
20 quinolone

To a solution of 4-carboxymethoxy-7-chloro-3-phenyl-2(1H)-quinolone (0.93g Example 15) in tetrahydrofuran (50ml) under nitrogen at room temperature, was added triethylamine (1.90ml), ammonium acetate (0.50g), 1-hydroxybenzotriazole (0.60g) and 1-(3 dimethylaminopropyl)-3-ethyl carbodiimide (0.90g). The reaction mixture was stirred at room temperature
25 for 3 days, then poured into water (100ml) and extracted with

SUBSTITUTE SHEET

- 65 -

ethyl acetate (3 x 50ml). The combined organic layers were washed with 1N citric acid (1 x 75ml), water (1 x 75ml), saturated sodium hydrogen carbonate (1 x 75ml) and brine (1 x 75ml), then dried (MgSO_4), filtered and the solvent was removed in vacuo to leave a solid residue. Recrystallisation from MeOH gave the title compound (0.29g). Mp 262-264°C. Found: C, 66.31; H, 5.95; N, 7.46; $\text{C}_{19}\text{H}_{19}\text{N}_2\text{O}_2\text{Cl} \cdot 0.1\text{C}_6\text{H}_{14} \cdot 0.6\text{H}_2\text{O}$ requires C, 65.97; H, 5.93; N, 7.85%. δ (360 MHz, DMSO- d_6) 3.91 (2H, s, $\text{OCH}_2\text{CONH}_2$), 7.25-7.45 (9H, m, Ph + 6-H + 8-H + $\text{OCH}_2\text{CONH}_2$), 8.01 (1H, d, $J = 8.66\text{Hz}$, 5-H), 11.92 (1H, bs, NH). m/z (CI^+), 329, (M+1).

EXAMPLE 35

7-Chloro-4-methoxyaminocarbonylmethoxy-3-phenyl-2(1H)-quinolone

To a solution of 4-carboxymethoxy-7-chloro-3-phenyl-2(1H)-quinolone (Example 15, 1.83g) in tetrahydrofuran (150ml) under nitrogen at room temperature, was added triethylamine (3.65ml), O-methyl hydroxylamine hydrochloride (0.96g), 1-hydroxybenzotriazole (1.15g) and 1-(3 dimethylaminopropyl)-3-ethyl carbodiimide (1.73g). The reaction mixture was stirred at room temperature for 16h, then poured into water (150ml) and extracted with ethyl acetate (3 x 100ml). The combined organic layers were washed with water (1 x 100ml), 1N citric acid (1 x 100ml), brine (1 x 100ml) and a saturated sodium hydrogen

SUBSTITUTE SHEET

- 66 -

carbonate solution (1 x 50ml), dried (MgSO_4), filtered and the solvent was removed in vacuo to leave a solid residue. Recrystallisation from ethyl acetate gave the title compound (0.12g). Mp 205-207°C. m/z (CI^+), 359, (m+1). ^1H NMR (360 MHz, $\text{DMSO}-d_6$) δ 3.32 (3H, s, $\text{NHOC}\underline{\text{H}}_3$), 3.93 (2H, s, $\text{OCH}_2\text{CONHOC}\underline{\text{H}}_3$), 7.23 (1H, dd, $\underline{J} = 8.63\text{Hz}$, $\underline{J} = 1.83\text{Hz}$, 6- $\underline{\text{H}}$), 7.36-7.45 (6H, m, Ph + 8- $\underline{\text{H}}$), 8.00 (1H, d, $\underline{J} = 8.63\text{Hz}$, 5- $\underline{\text{H}}$), 11.26 (1H, bs, $\text{OCH}_2\text{CONHOC}\underline{\text{H}}_3$), 11.94 (1H, bs, NH). Found: C, 60.57; H, 4.26; N, 7.82; $\text{C}_{18}\text{H}_{15}\text{N}_2\text{O}_4\text{Cl}$ requires C, 60.26; H, 4.21; N, 7.81%.

EXAMPLE 36

7-Chloro-4-(2-carboxy)ethyl-3-phenyl-2(1H)-quinolone

A. 5-Chloro-2-hydroxymethyl aniline

To a solution of 4-chloro-2-nitro benzyl alcohol (25.00g) in methanol (1 ltr) under nitrogen at room temperature, was added platinum on sulfided carbon (2.5g, 10% by wt). The reaction mixture was shaken under 50 psi of hydrogen until the theoretical uptake of hydrogen had occurred. Filtration, then removal of the solvent in vacuo afforded the desired compound as a solid (21.00g). δ (360 MHz, $\text{DMSO}-d_6$) 4.35 (2H, d, $\underline{J} = 4.95\text{Hz}$, CH_2OH), 5.17 (1H, t, $\underline{J} = 4.95\text{Hz}$, CH_2OH), 6.77 (1H, dd, $\underline{J} = 7.98\text{Hz}$, $\underline{J} = 2.18\text{Hz}$, 4- $\underline{\text{H}}$), 7.06 (1H, d, $\underline{J} = 2.18\text{Hz}$, 6- $\underline{\text{H}}$), 7.18 (1H, d, $\underline{J} = 7.98\text{Hz}$, 3- $\underline{\text{H}}$), 8.08 (1H, bs, NH_2), 8.47 (1H, bs, NH).

SUBSTITUTE SHEET

- 67 -

B. N-(Benzylcarbonyl)-5-chloro-2-hydroxymethyl aniline

To a suspension of 5-chloro-2-hydroxymethyl aniline (8.00g) in dichloromethane (400ml) under nitrogen at room temperature, was added triethylamine (15.6ml). The reaction mixture was cooled to 0°C then phenyl acetyl chloride (14.80ml) was added dropwise over 10 mins, and the reaction mixture was allowed to warm to room temperature and stir for 2h. The mixture was washed with 1N HCl (2 x 250ml) and brine (1 x 250ml). The aqueous layers were re-extracted using CH₂Cl₂ (1 x 250ml) and the combined organic layers were dried (MgSO₄), filtered and the solvent was removed under vacuum to leave an orange solid. The solid was suspended in MeOH (400ml), sodium hydroxide (2.20g) was added in water (100ml) and the reaction mixture was allowed to stir under gentle heating (50°C) for 45 mins. The methanol was removed in vacuo, then the aqueous residue was extracted with dichloromethane (1 x 200ml) and the organic layer was washed with brine (1 x 150ml) and saturated sodium hydrogen carbonate solution (1 x 150ml). The organic layer was dried (MgSO₄), filtered and the solvent was removed under vacuum to leave a solid. Trituration with diethyl ether gave the required compound (10.00g).

C. 2-(Benzylcarbonylamino)-4-chloro benzaldehyde

To a solution of N-(benzylcarbonyl)-5-chloro-2-hydroxymethyl aniline (15.50g) in dichloromethane (400ml)

SUBSTITUTE SHEET

- 68 -

under nitrogen at room temperature, was added pyridinium chlorochromate (24.30g) and crushed 4A molecular sieves (0.50g). The reaction mixture was stirred at room temperature for 90 mins, then ethyl acetate added, and the solution was filtered through a 2 inch plug of silica gel. The solvent was removed in vacuo and the material was redissolved in ethyl acetate and filtered through silica gel. Removal of the solvent under vacuum and trituration of the solid residue with diethyl ether gave the desired compound (10.50g). δ (360 MHz, DMSO- d_6) 3.82 (2H, s, NHCOCH_2Ph), 7.27-7.39 (6H, m, Ph + 5-H), 7.87 (1H, d, $J = 8.30\text{Hz}$, 6-H), 8.36 (1H, d, $J = 1.87\text{Hz}$, 3-H), 9.89 (1H, s, CHO), 10.97 (1H, bs, NHCOCH_2Ph).

D. N-Benzylcarbonyl)-5-chloro-2-(3-ethoxycarbonyl-1-hydroxy-propyl)-aniline

To a solution of 2-(benzylcarbonylamino)-4-chloro-benzaldehyde (10.50g) in dichloromethane (100ml) under nitrogen at 78°C was added TiCl_4 (4.3ml) then 1-1[1-(Ethoxycyclopropane)oxy]-trimethylsilane (8.80ml) in dichloromethane (30ml) was added dropwise, over 10 mins. The reaction mixture was stirred at -78°C for 15 mins, then allowed to warm to 0°C and stirred for 45 mins, then allowed to warm to room temperature and stirred for 3h. A saturated solution of ammonium chloride was added (100ml) then the aqueous and organic layers were partitioned and the aqueous layer was re-extracted with dichloromethane (2 x 75ml). The combined

- 69 -

organic layers were dried (MgSO_4), filtered and the solvent was removed in vacuo. Purification by silica gel flash chromatography (using 20-60% EtOAc in hexane as eluent) gave the desired compound as an oil (7.78g). δ (360 MHz, DMSO- d_6) 1.16 (3H, t, $J = 7.10\text{ Hz}$, $\text{CH(OH)CH}_2\text{CH}_2\text{CO}_2\text{CH}_2\text{CH}_3$), 1.60 (2H, m, $\text{CH(OH)CH}_2\text{CH}_2\text{CO}_2\text{Et}$), 2.15-2.33 (2H, m, $\text{CH(OH)CH}_2\text{CH}_2\text{CO}_2\text{Et}$), 3.70 (2H, s, NHCOCH_2Ph), 4.01 (2H, q, $J = 7.10\text{ Hz}$, $\text{CH(OH)CH}_2\text{CH}_2\text{CO}_2\text{CH}_2\text{CH}_3$), 4.68 (1H, bs, CH(OH)CH_2), 5.73 (1H, bs, CH(OH)CH_2), 7.16-7.34 (7H, m, Ph + 4-H + 6-H), 7.79 (1H, d, 3-H), 9.68 (1H, bs, NHCOCH_2Ph).

E. N-(Benzylcarbonyl)-5-chloro-2-[(3-ethoxycarbonyl-1-carbonyl)propyl]-aniline

15

To a solution of N-benzylcarbonyl)-5-chloro-2-(3-ethoxycarbonyl-hydroxypropyl)-aniline (8.80g) in dichloromethane (400ml) under nitrogen at room temperature, was added pyridinium chlorochromate (10.10g) and crushed 4A molecular sieves (0.50g). The reaction mixture was stirred at room temperature for 3h, then a further aliquot of pyridinium chlorochromate was added (2.53g) and the reaction mixture was stirred at room temperature for a further 16h. Ethyl acetate (100ml) was added, then the mixture was filtered through a 1 inch plug of silica gel and the solvent was removed in vacuo to give the desired compound as a solid (8.00g). δ (360 MHz, DMSO- d_6) 1.19 (3H, t, $J = 7.1\text{ Hz}$), 2.59 (2H, t, $J = 6.4\text{ Hz}$), 3.26 (2H, t, $J = 6.4\text{ Hz}$), 3.76 (2H, s), 4.06 (2H, q, $J = 7.1\text{ Hz}$), 7.27-7.37

SUBSTITUTE SHEET

- 70 -

(6H, m), 8.06 (1H, d, $J = 8.6\text{Hz}$), 8.47 (1H, s), 11.30 (1H, s); m/z (CI⁺) 374 (M+1).

5 F. 7-Chloro-4-[(2-ethoxycarbonyl)ethyl]-3-phenyl-2(1H)-quinolone

To a solution of N-(benzylcarbonyl)-5-chloro-3-[(3-ethoxycarbonyl-1-carbonyl)propyl]-aniline (8.00g, 21.42mmol) in EtOH (200ml) at room temperature was added an 80% dispersion of NaH (1.42g). The reaction mixture was stirred at
10 room temperature for 1h, then ethanolic hydrogen chloride was added (50ml) and the solvent was removed in vacuo to leave a solid residue. The residue was partitioned between ethyl acetate (200ml) and H₂O (200ml) and the aqueous was back
15 extracted with ethyl acetate (1 x 200ml). The combined organic layers were washed with water (1 x 150ml) and brine (1 x 150ml), dried (MgSO₄), filtered and the solvent was removed in vacuo to give the desired compound (7.6g). δ (360 MHz, DMSO-
d₆) 1.08 (3H, t, $J = 7.11\text{Hz}$, CH₂CH₂CO₂CH₂CH₃), 2.43 (2H, t, $J = 8.25\text{Hz}$, CH₂CH₂CO₂Et), 2.86 (2H, t, $J = 8.25\text{Hz}$,
20 CH₂CH₂CO₂Et), 3.95 (2H, t, $J = 7.11\text{Hz}$, CH₂CH₂CO₂CH₂CH₃), 7.22-7.47 (7H, m, Ph + 6-H + 8-H), 7.81 (1H, d, $J = 9.76\text{Hz}$, 5-H), 11.98 (1H, bs, NH).

25 G. 7-Chloro-4-(2-carboxy)ethyl-3-phenyl-2(1H)-1-quinolone

To a solution of 7-chloro-4-[(2-ethoxycarbonyl)ethyl]-3-phenyl-2(1H)-quinolone (7.60g) in ethanol (500ml) at room

SUBSTITUTE SHEET

- 71 -

temperature was added sodium hydroxide and water (100ml). The reaction mixture was stirred at room temperature for 3h, then a further aliquot of sodium hydroxide (3.50g) was added and the reaction mixture was stirred at room temperature for a further 16h. The ethanol was removed in vacuo and the aqueous residue was acidified to pH 1 using 5N HCl. Filtration of the emerging precipitate gave the desired compound (5.50g); mp 316-318°C. Found: C, 65.99; H, 4.36; N, 4.29. $C_{18}H_{14}ClNO_3$ requires C, 65.96; H, 4.31; N, 4.27%. δ (360 MHz, DMSO- d_6) 2.37 (2H, t, $J = 8.6$ Hz), 2.83 (2H, t, $J = 8.6$ Hz), 7.22-7.28 (3H, m), 7.36-7.46 (4H, m), 7.82 (1H, d, $J = 8.7$ Hz), 11.95 (1H, br, s). m/z (Cl^+) 328 (M+1).

EXAMPLE 37

15

7-Chloro-4-[(2-methoxycarbonyl)ethyl]-3-phenyl-2(1H)-quinolone

20

7-Chloro-4-[(2-ethoxycarbonyl)ethyl]-3-phenyl-2(1H)-quinolone (Example 36, part F, 1.17g) was dissolved in a saturated solution of hydrogen chloride in dry methanol (100ml) and stood at room temperature for 3h. Evaporation of the solvents and recrystallisation of the residue from methanol gave the required product (0.42g); mp 193-194°C; Found: C, 67.38; H, 4.75; N, 4.11. $C_{19}H_{16}ClNO_3 \cdot 0.1H_2O$ requires C, 67.18; H, 5.01; N, 4.00%. δ (360 MHz, DMSO- d_6) 2.47 (2H, t, $J = 8.4$ Hz), 2.88 (2H, t, $J = 8.4$ Hz), 3.52 (3H, s), 7.21-7.27 (3H, m), 7.36-7.46 (4H, m), 7.82 (1H, d, $J = 8.8$ Hz), 11.94 (1H, br, s); m/z (Cl^+) 342 (M+1).

30

SUBSTITUTE SHEET

- 72 -

EXAMPLE 384-(2-Aminocarbonyl)ethyl-7-chloro-3-phenyl-2(1H)-quinolone

5

To a solution of 7-chloro-4-(2-carboxy)ethyl-3-phenyl-2(1H)-quinolinone (1.70g) in tetrahydrofuran (100ml) under nitrogen at room temperature, was added triethylamine (3.25ml), ammonium acetate (0.80g), 1-hydroxybenzotriazole (1.05g) and 1-(3-N,N dimethylaminopropyl)-3-ethyl carbodiimide (1.49g). The reaction mixture was stirred at room temperature for 24h, the more ammonium acetate (0.20g), 1-hydroxybenzotriazole (0.35g) and 1-(3-N,N dimethylaminopropyl)-3-ethyl carbodiimide (0.49g) was added. The reaction mixture was stirred at room temperature for a further 48h, then poured into water (100ml) and extracted with ethyl acetate (3 x 100ml). The combined organic layers were washed with 1N citric acid (1 x 100ml), water (1 x 100ml), saturated sodium hydrogen carbonate solution (1 x 100ml) and brine (1 x 100ml) then dried (MgSO₄), filtered and the solvent was removed in vacuo. Recrystallisation from MeOH gave the title compound (0.05g). Mp 297-299°C. Found: C, 66.31; H, 5.95; N, 7.46; C₁₉H₁₉N₂O₂Cl 0.1C₆H₁₄0.6H₂O requires C, 65.97; H, 5.93; N, 7.85%. δ (360 MHz, DMSO-d₆) 2.21 (2H, t, J = 8.30Hz, CH₂CH₂CONH₂), 2.77 (2H, t, J = 8.30Hz, CH₂CH₂CONH₂), 6.78 (1H, bs, CH₂CH₂CONH₂), 7.21-7.46 (8H, m, Ph + 6-H + 8-H + CONH₂), 7.81 (1H, d, J = 8.84Hz, 5-H), 11.92 (1H, bs, NH). m/z (CI⁺), 327, (M+1).

25

SUBSTITUTE SHEET

- 73 -

EXAMPLE 397-Chloro-4-(2-cyanoethyl)-3-phenyl-2(1H)-quinolone

5 To a solution of 4-(2-aminocarbonyl)ethyl-7-chloro-3-phenyl-
2(1H)-quinolone (Example 38, 0.60g) in tetrahydrofuran (80ml)
under nitrogen at 0°C, was added triethylamine (1.13ml)
followed by trifluoroacetic anhydride (0.70ml). The reaction
mixture was stirred at 0°C for 45 mins, then poured into water
10 (100ml) and extracted with diethyl ether (2 x 100ml). The
combined organic layers were washed with water (1 x 100ml)
and brine (1 x 100ml), dried (MgSO₄), filtered and the solvent
was removed in vacuo. Recrystallisation from a water/methanol
mixture gave the title compound (0.08g). Mp 252-254°C.
15 Found: C, 70.26; H, 4.38; N, 9.04; C₁₈H₁₃N₂OCl requires C,
70.02; H, 4.24; N, 9.07%. δ (360 MHz, DMSO-d₆) 2.66 (2H, t, J =
7.65Hz, CH₂CH₂CN), 2.96 (2H, t, J = 7.65Hz, CH₂CH₂CN),
7.24-7.48 (7H, m, Ph + 6-H + 8-H), 7.91 (1H, d, J = 8.79Hz, 5-H),
12.03 (1H, bs, NH). m/z (Cl⁺), 327, (M+1).

20

EXAMPLE 407-Chloro-3-phenyl-4-(2-tetrazol-5-yl)ethyl-quinolin-2(1H)-
one

25

To a solution of 7-chloro-4-(2-cyanoethyl)-3-phenyl-quinolin-
2(1H)-one (Example 39, 0.45g) in 1-methyl-2-pyrrolidinone

SUBSTITUTE SHEET

- 74 -

(50ml) under nitrogen at room temperature, was added sodium azide (0.28g) followed by triethylamine hydrochloride (0.30g). The reaction mixture was heated to 150°C and stirred for 48h. After allowing to cool, the mixture was poured into water (100ml), acidified to pH 1 with concentrated HCl and extracted with ethyl acetate (3 x 75ml). The combined organic layers were extracted with 1N sodium hydroxide (3 x 75ml) and the combined aqueous phases were washed with diethyl ether (2 x 75ml), then acidified to pH 1 using concentrated HCl. The aqueous layer was extracted with ethyl acetate (3 x 75ml) and the combined organic layers were dried (MgSO₄), filtered and the solvent was removed in vacuo to leave a solid residue. Recrystallisation from a water/methanol mix then from ethyl acetate gave the title compound (0.05g). Mp 231-233°C. Found: C, 61.31; H, 4.20; N, 19.41; C₁₈H₁₄N₅OCl. 0.1 H₂O requires C, 61.14; H, 4.05; N, 19.81%. δ (360 MHz, DMSO-d₆) δ 3.05 (4H, bs, CH₂CH₂Tet), 7.10-7.42 (7H, m, Ph + 6-H + 8-H), 7.86 (1H, d, J = 8.73Hz, 5-H), 12.00 (1H, bs, NH). m/z (CI⁺), 352, (M+1).

EXAMPLE 41

7-Chloro-4-[2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-3-phenyl-2(1H)-quinolone

To a solution of acetamide oxime (0.26g) in tetrahydrofuran (50ml) under nitrogen at room temperature was added an 80%

SUBSTITUTE SHEET

- 75 -

dispersion of sodium hydride (0.14g). The reaction mixture was heated to 60°C, stirred for 90 mins then 7-chloro-4-(2-methoxycarbonyl)ethyl)-3-phenyl-2(1H)-quinolone was added (Example 37, 0.50g) and the reaction mixture was stirred at 60°C for 3h. After allowing to cool, the mixture was poured into water (100ml) and extracted with ethyl acetate (3 x 75ml). The combined organic layers were washed with 1N citric acid (1 x 75ml), water (1 x 75ml), saturated sodium hydrogen carbonate solution (1 x 75ml) and brine (1 x 75ml), then dried (MgSO₄), filtered and the solvent was removed in vacuo to leave a solid residue. Recrystallisation from an ethyl acetate/methanol mixture gave the title compound as a white solid (0.08g). Mp 235-238°C. Found: C, 65.38; H, 4.41; N, 11.35; C₂₀H₁₆N₃O₂Cl requires C, 65.67; H, 4.41; N, 11.49%. δ (360 MHz, DMSO-d₆) 2.25 (3H, s, CH₃), 3.04 (4H, m, CH₂, CH₂), 7.16 (1H, dd, J = 8.77Hz, J = 1.33Hz, 6-H), 7.18-7.44 (6H, m, Ph + 8-H), 7.87 (1H, d, J = 8.77Hz, 5-H), 12.00 (1H, bs, NH). m/z (Cl⁻), 365 (m).

Tablet Preparation

Tablets containing 1.0, 2.0, 25.0, 26.0, 50.0 and 100.0mg, respectively of the following compounds are prepared as illustrated below:

4-Amino-7-chloro-3-(3-phenoxyphenyl)-2(1H)-quinolone

7-Chloro-4-cyanomethoxy-3-(3-phenoxy)phenyl-2(1H)-quinolone

SUBSTITUTE SHEET

- 76 -

7-Chloro-4-[2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-3-phenyl-
2(1H)-quinolone

TABLE FOR DOSES CONTAINING FROM
1-25MG OF THE ACTIVE COMPOUND

5

		Amount-mg		
10	Active Compound	1.0	2.0	25.0
	Microcrystalline cellulose	49.25	48.75	37.25
	Modified food corn starch	49.25	48.75	37.25
	Magnesium stearate	0.50	0.50	0.50

TABLE FOR DOSES CONTAINING FROM
26-100MG OF THE ACTIVE COMPOUND

15

		Amount-mg		
20	Active Compound	26.0	50.0	100.0
	Microcrystalline cellulose	52.0	100.0	200.0
	Modified food corn starch	2.21	4.25	8.5
	Magnesium stearate	0.39	0.75	1.5

25 All of the active compound, cellulose, and a portion of the
corn starch are mixed and granulated to 10% corn starch paste.
The resulting granulation is sieved, dried and blended with the
remainder of the corn starch and the magnesium stearate. The
resulting granulation is then compressed into tablets containing

SUBSTITUTE SHEET

- 77 -


1.0mg, 2.0mg, 25.0mg, 26.0mg, 50.0mg and 100mg of the active ingredient per tablet.

SUBSTITUTE SHEET

- 78 -

CLAIMS:

1. A method for the treatment and/or
 5 prevention of conditions which require the administration
 of a selective non-competitive antagonist of NMDA
 receptors, which comprises administering to a patient in
 need of such treatment an effective amount of a compound
 of formula I or a pharmaceutically acceptable salt
 10 thereof or a prodrug thereof:



(I)

wherein

R represents a hydrogen atom, an amino group, a
 carboxy or C₂₋₆ alkoxy carbonyl group, or a group of
 formula -A-B-E, in which

25 A represents a chemical bond, an oxygen or
 sulphur atom, or an -NH- group;

B represents a carbonyl (C=O) or sulphonyl
 (SO₂) group, or a straight or branched alkylene chain
 containing from 1 to 6 carbon atoms; and

30 E represents C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆
 alkynyl, cyano, phenyl, tetrazolyl, methyloxadiazolyl,
 -NR^aR^b, -COR^a, -C(=N.OR^a)R^b, -CO₂R^a, -CONR^aR^b, -CONR^a.OR^b or
 -CH₂CO₂R^a;

- 79 -

R¹ and R² independently represent hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, -OR^a, -SR^a, -SOR^a, -SO₂R^a, -SO₂NR^aR^b, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -COR^a, -CO₂R^a or
5 -CONR^aR^b; or R¹ and R² together represent the residue of a carbocyclic or heterocyclic ring;

one of R³, R⁴, R⁵ and R⁶ represents hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, -OR^a, -SR^a, -SOR^a, -SO₂R^a, -SO₂NR^aR^b, -NR^aR^b, -NR^aCOR^b,
10 -NR^aCO₂R^b, -COR^a, -CO₂R^a or -CONR^aR^b, and the other three of R³, R⁴, R⁵ and R⁶ independently represent hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, -OR^a, -SR^a, -SOR^a, -SO₂R^a, -SO₂NR^aR^b, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -COR^a, -CO₂R^a or
15 -CONR^aR^b; and

R^a and R^b independently represent hydrogen, hydrocarbon or a heterocyclic group;


2. A method for the treatment and/or
20 prevention of conditions which require the administration of an antagonist of AMPA receptors, which comprises administering to a patient in need of such treatment an effective amount of a compound of formula I as defined in claim 1 or a pharmaceutically acceptable salt thereof or
25 a prodrug thereof.

3. The use of a compound of formula I as
defined in claim 1 or a pharmaceutically acceptable salt thereof or a prodrug thereof for the manufacture of a
30 medicament for the treatment and/or prevention of conditions which require the administration of a selective non-competitive antagonist of NMDA receptors.

- 80 -

4. The use of a compound of formula I as defined in claim 1 or a pharmaceutically acceptable salt thereof or a prodrug thereof for the manufacture of a medicament for the treatment and/or prevention of conditions which require the administration of an antagonist of AMPA receptors.

5. A pharmaceutical composition comprising a compound of formula IA or a pharmaceutically acceptable salt thereof or a prodrug thereof:



(IA)

wherein

R^{10} represents a hydrogen atom, an amino group, a carboxy or C_{2-6} alkoxy carbonyl group, or a group of formula -A-B-E, in which

25 A represents a chemical bond, an oxygen or sulphur atom, or an -NH- group;

B represents a carbonyl (C=O) or sulphonyl (SO_2) group, or a straight or branched alkylene chain containing from 1 to 6 carbon atoms; and

30 E represents C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, cyano, phenyl, tetrazolyl, methyloxadiazolyl, $-NR^aR^b$, $-COR^a$, $-C(=N.OR^a)R^b$, $-CO_2R^a$, $-CONR^aR^b$, $-CONR^a.OR^b$ or $-CH_2CO_2R^a$;

- 81 -

R¹¹ and R¹² independently represent hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, -OR^a, -SR^a, -SOR^a, -SO₂R^a, -SO₂NR^aR^b, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -COR^a, -CO₂R^a or
5 -CONR^aR^b; or R¹¹ and R¹² together represent the residue of a carbocyclic or heterocyclic ring;

one of R¹³, R¹⁴, R¹⁵ and R¹⁶ represents hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, -OR^a, -SR^a, -SOR^a, -SO₂R^a,
10 -SO₂NR^aR^b, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -COR^a, -CO₂R^a or -CONR^aR^b, and the other three of R¹³, R¹⁴, R¹⁵ and R¹⁶ independently represent hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, -OR^a, -SR^a, -SOR^a, -SO₂R^a, -SO₂NR^aR^b, -NR^aR^b, -NR^aCOR^b,
15 -NR^aCO₂R^b, -COR^a, -CO₂R^a or -CONR^aR^b; and

R^a and R^b independently represent hydrogen, hydrocarbon or a heterocyclic group;

provided that, when R¹⁰ represents a straight or branched alkoxy group containing 2 to 4 carbon atoms and
20 R¹¹, R¹², R¹³, R¹⁴ and R¹⁶ each represents hydrogen, then R¹⁵ does not represent an unsubstituted straight or branched alkoxy group containing 2 to 10 carbon atoms or a straight or branched alkoxy group containing 1 to 6 carbon atoms having at least one substituent selected
25 from hydroxy, carboxy and carbamoyl;
in association with one or more pharmaceutically acceptable carriers and/or excipients.


6. A compound of formula IA as defined in
30 claim 5 or a pharmaceutically acceptable salt thereof or a prodrug thereof for use in therapy.

7. A composition as claimed in claim 5 wherein the active ingredient is selected from:

- 82 -

7-chloro-3-(2-methoxyphenyl)-2(1H)-quinolone;
and pharmaceutically acceptable salts thereof and
prodrugs thereof.

- 5 8. A compound of formula IB or a salt or
prodrug thereof:



(IB)

wherein

R^{20} represents a hydrogen atom, an amino group,
a carboxy or C₂₋₆ alkoxy carbonyl group, or a group of
20 formula -A-B-E, in which

A represents a chemical bond, an oxygen or
sulphur atom, or an -NH- group;

B represents a carbonyl (C=O) or sulphonyl
(SO₂) group, or a straight or branched alkylene chain
25 containing from 1 to 6 carbon atoms; and

E represents C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆
alkynyl, cyano, phenyl, tetrazolyl, methyloxadiazolyl,
-NR^aR^b, -COR^a, -C(=N. OR^a)R^b, -CO₂R^a, -CONR^aR^b, -CONR^a.OR^b or
-CH₂CO₂R^a;

30 R^{21} and R^{22} independently represent hydrogen,
hydrocarbon, a heterocyclic group, halogen, cyano,
trifluoromethyl, nitro, -OR^a, -SR^a, -SOR^a, -SO₂R^a,
-SO₂NR^aR^b, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -COR^a, -CO₂R^a or

- 83 -

-CONR^aR^b; or R²¹ and R²² together represent the residue of a carbocyclic or heterocyclic ring;

one of R²³, R²⁴, R²⁵ and R²⁶ represents hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, -OR^a, -SR^a, -SOR^a, -SO₂R^a,
5 -SO₂NR^aR^b, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -COR^a, -CO₂R^a or -CONR^aR^b, and the other three of R²³, R²⁴, R²⁵ and R²⁶ independently represent hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl,
10 nitro, -OR^a, -SR^a, -SOR^a, -SO₂R^a, -SO₂NR^aR^b, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -COR^a, -CO₂R^a or -CONR^aR^b; and

R^a and R^b independently represent hydrogen, hydrocarbon or a heterocyclic group;

provided that, when R²¹ and R²² each represents hydrogen, then:

(i) R²⁵ does not represent an unsubstituted straight or branched alkoxy group containing 2 to 10 carbon atoms or a straight or branched alkoxy group containing 1 to 6 carbon atoms having at least one
20 substituent selected from hydroxy, carboxy and carbamoyl when R²⁰ represents a straight or branched alkoxy group containing 2 to 4 carbon atoms and R²³, R²⁴ and R²⁶ each represents hydrogen; and

(ii) R²⁰ does not represent carboxy when R²⁴ is iodo and R²³, R²⁵ and R²⁶ each represents hydrogen; and

(iii) R²⁰ does not represent amino or benzylamino when R²⁵ represents methyl or methoxy and R²³, R²⁴ and R²⁶ each represent hydrogen;


provided also that when R²¹ is 2'-methoxy and R²², R²³ and R²⁶ each represents hydrogen, then:

(i) R²⁰ does not represent hydrogen or carboxy when one of R²⁴ and R²⁵ represents fluoro or chloro and the other is hydrogen; and

- 84 -

(ii) R^{20} does not represent carboxy when one of R^{24} and R^{25} represents bromo or iodo and other is hydrogen.

9. A compound as claimed in claim 8
5 represented by formula IIA and salts and prodrugs thereof:



(IIA)

wherein

R^{31} represents C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, aryl(C_{1-6})alkyl, aryl(C_{2-6})alkenyl, aryl(C_{2-6})alkynyl, heteroaryl(C_{1-6})alkyl, C_{1-6} alkoxy, C_{2-6} alkenyloxy, aryloxy, aryl(C_{1-6})alkoxy, heteroaryloxy, C_{1-6} alkylthio, arylthio, arylsulphonyl, arylamino, aryl(C_{1-6})alkylamino, di(C_{1-6})alkylamino, arylcarbonylamino, arylcarbonyl, heteroarylcarbonyl or C_{2-7} alkoxy carbonyl, any of which groups may be optionally substituted; or hydrogen, halogen, cyano, trifluoromethyl, nitro, hydroxy, amino or carboxy; and

R^{32} represents C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, aryl(C_{1-6})alkyl, aryl(C_{2-6})alkenyl, aryl(C_{2-6})alkynyl, heteroaryl(C_{1-6})alkyl, C_{2-6} alkoxy, C_{2-6} alkenyloxy, aryloxy, aryl(C_{1-6})alkoxy, heteroaryloxy, C_{1-6} alkylthio, arylthio, arylsulphonyl, arylamino, aryl(C_{1-6})alkylamino, di(C_{1-6})alkylamino,

- 85 -

arylcarbonylamino, arylcarbonyl, heteroarylcarbonyl or C₂₋₇ alkoxy carbonyl, any of which groups may be optionally substituted; or halogen, cyano, trifluoromethyl, nitro, hydroxy, amino or carboxy; or

5 R³¹ and R³² together represent the residue of a carbocyclic or heterocyclic ring;


R³³ represents hydrogen, halogen, cyano, trifluoromethyl, nitro, hydroxy, amino, carboxy, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio or C₂₋₇ alkoxy carbonyl;

R³⁴ represents hydrogen or halogen; and

R³⁵ represents halogen, cyano, trifluoromethyl, nitro, hydroxy, amino, carboxy, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio or C₂₋₇ alkoxy carbonyl.

15

10. A compound as claimed in claim 8 represented by formula IIB and salts and prodrugs thereof:



(IIB)

30 wherein

A¹ represents a chemical bond, an oxygen atom or an -NH- group;

- 86 -

B¹ represents a carbonyl (C=O) or sulphonyl (SO₂) group, or a group of formula -(CH₂)_n- in which n is 1, 2, 3 or 4; and

E¹ represents C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, cyano, phenyl, tetrazolyl, methyloxadiazolyl, amino, C₁₋₆ alkylamino, di(C₁₋₆)alkylamino, C₁₋₆ alkanoyl, oximino(C₁₋₆)alkyl, C₁₋₆ alkyloximino(C₁₋₆)alkyl, carboxy, C₂₋₆ alkoxycarbonyl, aminocarbonyl, di(C₁₋₆)alkylaminocarbonyl, C₁₋₆ alkoxyaminocarbonyl, carboxymethyl or C₂₋₆ alkoxycarbonyl-methyl;

R⁴¹ and R⁴² independently represent C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, aryl(C₁₋₆)alkyl, aryl(C₂₋₆)alkenyl, aryl(C₂₋₆)alkynyl, heteroaryl(C₁₋₆)alkyl, C₁₋₆ alkoxy, C₂₋₆ alkenyloxy, aryloxy, aryl(C₁₋₆)alkoxy, heteroaryloxy, C₁₋₆ alkylthio, arylthio, arylsulphonyl, arylamino, aryl(C₁₋₆)alkylamino, di(C₁₋₆)alkylamino, arylcarbonylamino, arylcarbonyl, heteroarylcarbonyl or C₂₋₇ alkoxycarbonyl, any of which groups may be optionally substituted; or hydrogen, halogen, cyano, trifluoromethyl, nitro, hydroxy, amino or carboxy; or

R⁴¹ and R⁴² together represent the residue of a carbocyclic or heterocyclic ring;

R⁴³ and R⁴⁴ independently represent hydrogen, halogen, cyano, trifluoromethyl, nitro, hydroxy, amino, carboxy, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio or C₂₋₇ alkoxycarbonyl; and

R⁴⁵ represents halogen, cyano, trifluoromethyl, nitro, hydroxy, amino, carboxy, C₂₋₆ alkenyl, C₁₋₆ alkylthio or C₂₋₇ alkoxycarbonyl.

30

11. A compound as claimed in claim 8 selected from:

7-chloro-3-(2-hydroxyphenyl)-2(1H)-quinolone;
7-chloro-3-(4-hydroxyphenyl)-2(1H)-quinolone;

- 87 -

- 3-(2-aminophenyl)-7-chloro-2(1H)-quinolone;
3-(3-carboxyphenyl)-7-chloro-2(1H)-quinolone;
4-carboxy-7-chloro-3-phenyl-2(1H)-quinolone;
4-carboxymethyl-7-chloro-3-phenyl-2(1H)-quinolone;
5 7-chloro-4-methoxycarbonylmethyl-3-phenyl-2(1H)-
quinolone;
4-carboxymethoxy-7-chloro-3-phenyl-2(1H)-quinolone;
7-chloro-4-methoxycarbonylmethoxy-3-phenyl-2(1H)-
quinolone;
10 4-allyloxy-7-chloro-3-phenyl-2(1H)-quinolone;
4-amino-7-chloro-3-phenyl-2(1H)-quinolone;
4-amino-7-chloro-3-(2-methoxyphenyl)-2(1H)-quinolone;
4-amino-7-chloro-3-(3-phenoxyphenyl)-2(1H)-quinolone;
4-benzylamino-7-chloro-3-phenyl-2(1H)-quinolone;
15 7-chloro-4-(2-dimethylaminoethyl)amino-3-phenyl-2(1H)-
quinolone;
7-chloro-4-(3-dimethylaminopropyl)amino-3-phenyl-2(1H)-
quinolone;
4-acetylamino-7-chloro-3-phenyl-2(1H)-quinolone;
20 4-carboxymethylcarbonylamino-7-chloro-3-phenyl-2(1H)-
quinolone;
4-carboxycarbonylamino-7-chloro-3-phenyl-2(1H)-quinolone;
7-chloro-4-methoxycarbonylcarbonylamino-3-phenyl-2(1H)-
quinolone;
25 7-chloro-4-methylsulphonylamino-3-phenyl-2(1H)-quinolone;
7-chloro-3-phenyl-4-phenylsulphonylamino-2(1H)-quinolone;
7-chloro-4-methylcarbonylmethoxy-3-phenyl-2(1H)-
quinolone;
7-chloro-4-(2-oximinopropyl)oxy-3-phenyl-2(1H)-quinolone;
30 7-chloro-3-phenyl-4-(2-propynyl)oxy-2(1H)-quinolone;
7-chloro-4-(2-methyloximinopropyl)oxy-3-phenyl-2(1H)-
quinolone;
7-chloro-4-methoxycarbonylmethoxy-3-(3-phenoxyphenyl)-
2(1H)-quinolone;

- 88 -


- 4-carboxymethoxy-7-chloro-3-(3-phenoxyphenyl)-2(1H)-quinolone;
7-chloro-4-cyanomethoxy-3-phenyl-2(1H)-quinolone;
7-chloro-4-cyanomethoxy-3-(3-phenoxyphenyl)-2(1H)-
5 quinolone;
7-chloro-4-(N,N-dimethylaminocarbonyl)methoxy-3-phenyl-2(1H)-quinolone;
7-chloro-4-[2-(N,N-dimethylamino)ethoxy]-3-phenyl-2(1H)-quinolone;
10 4-aminocarbonylmethoxy-7-chloro-3-phenyl-2(1H)-quinolone;
7-chloro-4-methoxyaminocarbonylmethoxy-3-phenyl-2(1H)-quinolone;
7-chloro-4-(2-methoxycarbonyl)ethyl-3-phenyl-2(1H)-quinolone;
15 4-(2-carboxyethyl)-7-chloro-3-phenyl-2(1H)-quinolone;
4-(2-aminocarbonyl)ethyl-7-chloro-3-phenyl-2(1H)-quinolone;
7-chloro-4-(2-cyanoethyl)-3-phenyl-2(1H)-quinolone;
7-chloro-3-phenyl-4-[2-(1H-tetrazol-5-yl)ethyl]-2(1H)-
20 quinolone;
7-chloro-4-[2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-3-phenyl-2(1H)-quinolone;
and salts and prodrugs thereof.

- 25 12. A process for the preparation of a compound of formula I as defined in claim 1, which process comprises:

(A) cyclising a compound of formula III:

30


- 89 -



(III)

wherein R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are as defined in claim 1; and G^1 represents an aldehyde ($-CHO$) or cyano ($-CN$) group, or a group of formula $-CO-B^a-E$ in which B^a represents a straight or branched alkylene chain containing from 1 to 6 carbon atoms and E is as defined in claim 1; or

(B) intramolecular Michael cyclisation of a compound of formula IIIA:




(IIIA)

wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^6 and R^a are as defined in claim 1; in the presence of a strong base; followed by quenching with a selenyl halide reagent; and subsequent


- 90 -

elimination of selenium to afford the double bond in the 3,4-position; or

(C) reacting a compound of formula VI with a
5 compound of formula VA:




(VI)



(VA)

wherein R¹, R², R³, R⁴, R⁵ and R⁶ are as defined in claim 1; or

(D) reacting a compound of formula L-B-E with
20 a compound of formula VII:



(VII)

wherein R¹, R², R³, R⁴, R⁵, R⁶, B and E are as defined in claim 1; A¹⁰ represents an oxygen or sulphur atom or an -NH- group; and L represents a leaving group; or

- 91 -

(E) reacting a compound of formula H_2N-B-E , wherein B and E are as defined in claim 1, with a compound of formula VII as defined above in which A^{10} represents an oxygen atom; and

5

(F) where appropriate, converting a compound of formula I initially obtained into a further compound of formula I using methods known per se.

10